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A B S T R A C T
This review article describes the use of immune cells as potential candidates to deliver anti-cancer drugs deep
within the tumor microenvironment. First, the rationale of using drug carriers to target tumors and potentially
decrease drug-related side effects is discussed. We further explain some of the current limitations when using
nanoparticles for this purpose. Next, a comprehensive step-by-step description of the migration cascade of im-
mune cells is provided as well as arguments on why immune cells can be used to address some of the limitations
associated with nanoparticle-mediated drug delivery. We then describe the benefits and drawbacks of using red
blood cells, platelets, granulocytes, monocytes, macrophages, myeloid-derived suppressor cells, T cells and NK
cells for tumor-targeted drug delivery. An additional section discusses the versatility of nanoparticles to load
anti-cancer drugs into immune cells. Lastly, we propose increasing the circulatory half-life and development of
conditional release strategies as the two main future pillars to improve the efficacy of immune cell-mediated
drug delivery to tumors.
1. Off-target side effects limit drug efficacy
The current view of cancer is clearly that of a systemic disease [1].
Consequently, the containment of a cancerous mass or a tumor relies on
its interaction with non-cancerous cells of the body. Back-and-forth
communication between cancer cells and the cells in close proximity
establishes a tumor microenvironment (TME) which consists of the
extracellular matrix (ECM), fibroblasts, blood vessels and immune cells
[2]. Ultimately, the co-evolution and dynamic interaction of these TME
components will dictate the clinical progression of cancer.
Due to its heterogeneous nature, treatment of solid tumors requires
a multimodal approach where surgery and radiation therapy has to be
succeeded by adjuvant chemotherapy [3]. In search for decreasing the
sometimes severe side effects due to off-target action on healthy cells,
researchers in the 1980’s experimented with drug delivery vehicles
such as liposomes loaded with doxorubicin [4]. This coincided with the
large scale manufacturing of monoclonal antibodies [5] which opened
the gates to the identification of many additional therapeutic targets
and was the onset of tumor targeted drug delivery [6]. Mapping of the
human genome in the 1990s [7] facilitated the in-depth understanding
of the genetic basis of cancer and revealed many novel therapeutic
targets associated with this disease [8]. The increased knowledge on
preventing, diagnosing and treating cancer is reflected in the
substantially improved clinical outcome compared to that of half a
century ago (WHO-IARC). Nevertheless, there is still a formidable task
lying ahead since the majority of cancer-related mortality is currently
associated with metastatic disease [9–11], a far more elusive target
than the primary tumor.
When administrating drugs in vivo, the pharmacokinetics (i.e. the
mechanisms governing the absorption, distribution, metabolism and
excretion) of these compounds has to be carefully considered [12,13].
Typically, limited bioavailability and activity of therapeutics are a di-
rect result of their inappropriate physicochemical properties and their
fast clearance by e.g. enzymatic degradation, glomerular filtration and
phagocytosis by cells of e.g. the mononuclear phagocyte system (MPS)
[14]. Employing higher dosages, other administration routes or more
frequent administrations can increase the drug plasma concentration,
but also elicits more side effects. A common practice to treat cancer is
administrating the maximum tolerated dosing (MTD) of the che-
motherapeutic [15], which is the highest dose that does not cause un-
acceptable side effects within a specified time period [14,16–18].
However, drug dosages that are below complete efficacy (even at MTD)
cause selective pressure on the cancer cells when repeatedly used. By
evolutionary principle, sensitive cancer cells are weeded out while re-
sistant cancer cells remain intact, proliferate and compose a new tumor
resistant to the used therapeutic [18]. The genetic heterogeneity of
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cancer cells is even more pronounced when they spread across multiple
organs [11]. Employing combination therapies or frequently switching
to other drugs helps addressing this problem [19], but oncologists are
always limited by the MTD since off-target effects on healthy cells cause
side effects and thus diminish the dose at which the therapeutic agent
can be used. Moreover, as most anti-cancer drugs are administered
systemically, they come into contact with numerous healthy cells.
2. The tumor microenvironment as a more reliable therapeutic
target
Compared to the ever-changing cancer cells themselves, more stable
tumor properties can be found in the TME of both primary tumors and
metastatic niches [20–22]. For example, rapid tumor growth requires
an increased influx of nutrients and efflux of waste products. The for-
mation of new blood vessels to cope with this demand is frequently
inadequate and hence results in characteristic tumor-associated phe-
nomena such as hypoxia [23], high interstitial fluid tension [24] and
low pH [25]. In addition, tumor-associated blood vessels are frequently
leaky in nature [26] and exhibit morphological abnormalities such as a
lack in pericyte coverage, a serpentine course, irregular branching,
arterial-venous shunts and irregular perfusion (Fig. 1) [27,28]. More-
over, the lymphatic drainage of many solid tumors is often heavily
impaired [29]. Combined with the production and remodeling of the
ECM at the tumor margin [30,31], these anomalies lead to an increased
interstitial fluid pressure within the tumor [32,33].
As first described by Matsumura and Maeda [34], the leaky prop-
erties of the tumor vasculature can be exploited to more selectively
deliver biocompatible particles into solid tumors. This concept became
known as the “enhanced permeability and retention (EPR) effect” [26].
To achieve successful EPR-driven drug delivery, the used particles
mainly need long circulation times. Though distinct tumor accumula-
tion is already seen as soon as 30 minutes, exploitation of the EPR effect
requires drug delivery vehicles to circulate at least several hours in
mice. This is obtained when the particles are prevented from clearance
by the kidneys or the MPS, do not interact with blood vessels, are not
immunogenic and remain intact [26]. The resulting drug retention in
the tumor is reported to last several days to weeks [35]. In practice, the
used particles should be smaller than 780 nm to pass through the pores
of the tumor endothelium but larger than 40 kDa/5.5 nm to avoid their
rapid renal clearance [36–38]. A frequently used strategy to prolong
nanoparticle circulation time is to provide them with a shell of poly-
ethylene glycol (PEG), a polymer known to reduce opsonisation and
premature clearance by the MPS [39]. However, repeated administra-
tion of PEGylated agents can elicit an immune response leading to ac-
celerated blood clearance due to formation of anti-PEG antibodies [40].
About three decades ago, the EPR effect sparked the emergence of
the nanoparticle research field which was heavily reliant on the “pas-
sive targeting” provided by this effect. Since then, many strategies have
been devised to provide a complementary “active targeting” component
to the used nanoparticles (i.e. adding specific ligands which target
overexpressed receptors on cancer cells or in the TME) [36,41]. Despite
the initial enthusiasm, this field is currently confronted with skepticism
due to failure of providing relevant enhanced tumor accumulation in
the clinic [42,43]. Moreover, the added benefit of targeting ligands are
minimal compared to the physicochemical properties of nanoparticles
[36,44]. A comprehensive literature review corroborated these findings
and stated that even in mouse tumors, only 0.6% (median) of the in-
jected nanoparticles reach the tumor via passive targeting [45]. Em-
ploying active targeting strategies modestly raised this value to almost
1%, but no evolution in the delivery efficiency has been seen over the
span of 10 years [45]. This setback is even more pronounced in humans
and can be attributed to differences in tumor manifestation in pre-
clinical animal models compared to tumor growth in humans [45]. The
most notable differences relate to the relatively more heterogeneous
nature of human tumors compared to experimental rodent tumors and
include the smaller tumor-to-body size in humans, the absence of hy-
perpermeable vasculature, the high interstitial fluid pressure, the pre-
sence of avascular regions and the chaotic TME in human tumors
[42,46]. These unfortunate developments highlight the limitations of
animal models and emphasize the diverse nature of tumor biology.
They also generate novel opportunities such as normalization of the
tumor vasculature to increase tumor drug delivery [47–50]. In addition,
novel studies such as the one by Sindhwani et al. (2020) suggest that
almost all injected nanoparticles enter solid tumors via active en-
dothelial transcytosis instead of EPR [51]. Although these mechanisms
of nanoparticle transcytosis and their ability to specifically target tu-
mors still need clarification, they bear the potential to elicit a paradigm
shift in the nanoparticle research field [52].
Unlike small circulating compounds such as drugs, antibodies and
nanoparticles, larger immune cells do not rely on passive diffusion to
enter the TME but use their complex cellular machinery to navigate to
and through the tumor-associated endothelium to occupy specific re-
gions within the TME [53–57]. Consequently, immune cells potentially
provide solutions to the obstacles that emerged in the field of targeted
drug delivery. For example, immune cells do not require the presence of
endothelial pores to initiate extravasation [58], are able to migrate into
areas exerting high interstitial pressure and can even populate avas-
cular regions deep inside solid tumors [59]. Furthermore, since tumor
manifestation is often a form of unresolved chronic inflammation, im-
mune cells are continuously recruited to this site [60,61].
Fig. 1. Tumors display aberrant blood ves-
sels. In normal blood vessels, arteries size
down to arterioles and perfuse a capillary
bed which then drains into venules of the
venous system. A continuous layer of peri-
cytes within the basement membrane en-
circles these small blood vessels. In con-
trast, the vasculature of solid tumors
demonstrates a severely disarranged capil-
lary bed with typical tortuous (serpentine)
course, irregular branching and endothelial
pores. Moreover, tumor blood vessels are
poorly covered by pericytes and exhibit ar-
teriovenous shunts that bypass certain re-
gions of the capillary bed.
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3. How immune cells reach their target
Circulating immune cells respond to inflammation-associated cues
in a relatively uniform manner. However, some important distinctions
exist between different immune cell populations that have an effect on
their response time and trafficking patterns. For example, in contrast to
granulocytes, naive lymphocytes are poorly responsive to inflammatory
signals. They migrate efficiently to secondary lymphoid tissue where
they first need to be activated before they acquire the capacity to be
recruited to inflammation sites [62]. Immune cell trafficking occurs in
sequential steps where each step is conditional for the next and thus,
generates high targeting specificity (Fig. 2) [63]. These steps often take
place in postcapillary venules, small veins with a diameter of about 50
μm which are located directly after the sites of increased vascular
permeability during inflammation. The leakage of plasma and the wider
lumen increase hemoconcentration, slowing the blood flow and al-
lowing more interactions between the endothelium and leukocytes
[64]. In addition, hemodynamic forces confine red blood cells (RBCs) to
the center of the blood vessel, thereby “marginating” other large par-
ticles such as immune cells to the vessel walls [65].
Passing immune cells that come into contact with the endothelial
layer loosely bind sugar moieties, thereby inducing a reversible leu-
kocyte rolling along the endothelial surface lasting several seconds to
minutes [66,67]. This first step in the migration cascade is mediated by
selectins (CD62), cell surface molecules that bind distinct terminal
carbohydrate residues (a tetrasaccharide motif known as “sialylated
Lewis X”) of glycoproteins or glycolipids in a calcium-dependent
fashion [62,66]. Selectins are composed of three families named after
the cell type on which they were originally identified: E-selectin on
activated endothelium, P-selectin on activated platelets, but also on
activated endothelium and L-selectin constitutively on lymphocytes,
but also expressed on hematopoietic stem/progenitor cells [62,66]. The
carbohydrate selectin ligands are present on endothelial cells and other
leukocytes, thus facilitating leukocyte-endothelium or leukocyte-leu-
kocyte interactions [68]. Of all the available ligands, P-selectin glyco-
protein ligand 1 (PSGL-1) appears to be the main ligand for all these
selectins [69]. The non-covalent bonds forming between the rolling
leukocyte and the vessel wall must counteract the shear stress, the
horizontal force and torque exerted by the blood flow [70].
Interestingly, this involves selectin-associated “catch bonds” which re-
quire a certain amount of shear stress for leukocytes to attach to the
endothelium and may prevent inappropriate leukocyte aggregation or
extravasation during vascular stasis [68]. After reaching a maximal
shear stress value, selectin-ligand interactions change from “catch
bonds” to regular “slip bonds” [70]. This delicate balance makes the
cell pivot over the remaining binding sites and hence roll to a position
further downstream at about 10 μm/s. In addition to mediating re-
versible cell-cell adhesion, selectin binding also activates intracellular
signaling pathways leading to e.g. β2-integrin activation associated
with intermediate affinity [71,72]. Consequently, selectin-mediated
rolling further reduces rolling velocities to about 5 μm/s by facilitating
conformational changes in integrins and thus providing more oppor-
tunities for rolling cells to encounter endothelium-bound chemokines
[72,73]. In turn, the encountered inflammation-associated chemokines
which are displayed on the endothelium surface will further stimulate
integrin activation that mediates leukocyte arrest and subsequent
transendothelial migration [64].
Integrins are transmembrane cytoskeleton-linked heterodimers
consisting of paired α and β subunits. These subunits assemble into
many different receptors with different binding properties and tissue
distribution [74]. Essentially all nucleated cells express integrins [73],
but the β2- or CD18-integrins are only expressed on leukocytes [73,75].
For example, lymphocyte function-associated antigen 1 (LFA-1, αLβ2 or
CD11a/CD18) is expressed on all leukocytes and is the predominant
integrin on lymphocytes while macrophage-1 (Mac-1, CR3, αMβ2 or
CD11b/CD18) dominates on myeloid leukocytes [75]. Integrin activa-
tion induces rapid (i.e. within 1 s) conformational changes from a
completely bent form with low ligand affinity to an intermediate or
fully extended form with very high ligand affinity [74,76,77]. Most
integrins typically bind a wide variety of ligands, making these re-
ceptors essential in many cell-cell and cell-matrix interactions [74].
Though integrins can be involved in the rolling of leukocytes [78], they
are mostly important for inducing firm adhesions. Conformational
change of integrins is initiated by other cell surface receptors (e.g. se-
lectins, chemokine receptors, Toll-like receptors or the T cell receptor)
and occurs through cytoplasmic activation of the integrin β subunits
[75,79]. Once activated, the integrins can bind their endothelial ligands
such as members of the immunoglobulin superfamily (e.g. ICAM-1,
Fig. 2. The uniformly used migration cascade in normal postcapillary venules. (1) RBC concentration at the center of the venule and slower blood flow due to an
increased vessel diameter drive leukocytes to the vessel wall. Due to the laminar flow of blood, leukocytes slow down further when they come in close proximity with
the endothelium. (2) Leukocytes expressing L-selectin reversibly bind sugar moieties containing the SLEx motif on endothelial cells. Conversely, P- and E-selectin
expression on endothelial cells bind sugar moieties on leukocytes. In addition, the rolling of leukocytes is further mediated by low-affinity integrins. (3)
Inflammation-associated chemokines are presented on the luminal surface of activated endothelial cells. Rolling leukocytes that bind these chemokines on cognate
receptors become activated and express integrins in a high-affinity conformation. (4) High-affinity integrins on the leukocyte cell surface bind ligands on the
endothelial cells (e.g. Cellular Adhesion Molecules). This induces firm adhesions which keep the leukocyte stationary. (5) Firmly attached activated leukocytes will
spread out and start Mac-1-mediated crawling along the vessel wall to find a suitable extravasation site. Crawling occurs with or against the blood flow. (6)
Leukocytes squeeze their way in between (or through) endothelial cells via PECAM-PECAM interactions. Next, the leukocytes slowly navigate their way through the
basement membrane until they find a gap in between pericytes. (7) Traversing the ECM requires coordinated integrin expression and apical proteolysis. Alternatively,
the leukocyte can crawl through ECM pores in an amoeboid way. The direction of migration follows a gradient of chemoattractant molecules in the ECM. RBC: red
blood cells, SLEx: Sialylated Lewis X, Mac-1: Macrophage-1 receptor, PECAM: platelet endothelial cell adhesion molecule, ECM: extracellular matrix.
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VCAM-1 and MAdCAM-1) [75]. At inflammatory sites, this is followed
by cell spreading and Mac-1-mediated crawling along the vessel wall to
find suitable extravasation sites [80,81].
Most of the immune cells that pass through the vasculature of the
inflammation site do not roll, most of those that roll do not adhere and
most of the adherent immune cells do not extravasate [82]. However,
the commitment of immune cells to initiate extravasation marks a
certain “point of no return” [82]. Transendothelial migration or dia-
pedesis is initiated by clustering of leukocyte integrins with their en-
dothelial ligands and occurs in between (para-) or to a lesser extent
through (trans-) endothelial cells [83,84]. The resulting actin-rich en-
dothelial docking structures then form a tight ring around the trans-
migrating leukocyte [64]. VE-cadherin (CD144) normally connects
endothelial cells at adherens junctions, but is cleared from the site of
transmigration to form a gap. In addition, a dynamic vesicle complex
known as the lateral border recycling compartment at the intercellular
junctions between endothelial cells has to assemble around the extra-
vasating leukocyte and continuously recycle to facilitate transen-
dothelial migration [64]. This requires PECAM-PECAM or CD31 inter-
actions between the leukocytes and the endothelium as well as an
essential increase of intracellular calcium in the endothelial cells [64].
Once the immune cell has successfully crossed the endothelial layer
within less than 5 minutes, it must also find a way through the basal
lamina. In general, this can take up to 15 minutes as the leukocyte has
to navigate its way to areas with less collagen IV and laminin 511 de-
position [85–88]. These areas frequently occur at gaps in pericyte
coverage and squeezing through these gaps involves many of the mo-
lecules seen for transendothelial migration [64,89]. In addition, leu-
kocytes require deformable nuclei to traverse these narrow pores and
can rely on protease-mediated remodeling of the basement membrane
to clear the path [89].
After immune cells have penetrated the dense sheet-like basement
membrane, migration through the rest of the interstitial mesh-like ECM
starts. The ECM is a highly complex organ-specific network of fibrillary
and non-fibrillary collagens, glycoproteins and proteoglycans as-
sembled in supramolecular structures which provide structural support,
but also bind and regulate the distribution of soluble factors such as
growth factors and chemokines [87,90]. Immune cell migration
through the ECM is achieved by coordinated expression of certain
collagen-binding and –sensing integrins [87]. In addition, secreted and
membrane-bound proteases e.g. matrix metalloproteinases can help in
clearing the path [91]. In turn, this localized proteolysis of the extra-
cellular matrix exposes more integrin ligands, cytokines and chemo-
kines which elicit a combined directional response in the migrating
leukocyte [92,93]. Active breakdown of the ECM and integrin-mediated
attachment is not always a requirement as leukocytes can also navigate
through pre-existing matrix gaps in an amoeboid way independent of
matrix-degrading enzymes or even integrins [94]. Nonetheless, cell
type-specific limitations in nuclear stiffness impose protease activity as
ECM pores are typically smaller than 1 μm [87,95].
Chemotaxis is the movement of an immune cell in response to
chemical substances present in tissues (chemoattractants). Secreted
cytokines that elicit such chemotaxis are termed chemokines and ty-
pically bind cellular G protein-coupled receptors [96]. They are sub-
divided into four classes based on the spacing between the first 2 cy-
steine (C) residues at the amino terminus. These 2 cysteines are
separated by either zero, one or three amino acids in respectively C,
CXC and CX3C chemokines. C chemokines have only one cysteine at the
N-terminus [97]. Chemokines are constitutively expressed under
homeostatic conditions to maintain immune surveillance, but activated
cells can also produce inflammatory chemokines to recruit additional
immune cells to inflamed tissues [96].
Leukocytes first encounter chemokines, produced by interstitial or
vascular cells, while rolling on the endothelial surface at sites of in-
flammation [98]. This interaction activates integrins, thereby initiating
transendothelial migration. Upon arriving in the ECM, immune cells
sense gradients of chemotactic cues in a cell type-specific manner and
migrate towards the region of highest concentration [96,98]. As many
chemoattractants influence the chemotaxis simultaneously, migrating
immune cells have the capacity to hierarchically prioritize certain
chemokine gradients [96]. Interestingly, migrating immune cells may
also release chemokines themselves, allowing other immune cells to
follow their trail [99]. To establish a gradient, soluble chemokines need
to diffuse away from their source. To prevent chemokines from washing
away, they are immobilized in the ECM and on the luminal surface of
endothelial cells via glucosaminoclycans [96,100]. Nevertheless, dis-
lodged chemokines are also detected in the blood during inflammation.
These blood-borne chemokines are suspected of activating immune
cells off-site and by doing so, causing immune cell accumulation in
organs such as the lungs and the liver [96].
4. Hijacking cells for drug delivery purposes
Immune cells are continuously recruited to establish a TME that can
be either anti- or pro-tumorigenic. Tumors can be pathologically cate-
gorized according to the relative presence of these different recruited
immune cell populations and the character of their inflammatory re-
sponse [101–103]. For example, tumors that are heavily populated by T
lymphocytes are considered immunologically “hot” whereas “cold”
tumors are characterized by an absence of these cells. In between these
2 extremes, we find “infiltrated-excluded” TMEs which are heavily
populated by lymphocytes at their periphery but lack cytotoxic lym-
phocytes (CTLs) in the tumor core [104]. In addition, “infiltrated-im-
munosuppressed” TMEs contain a low number of lymphocytes with
suppressed effector function in the tumor core [101]. Tumor eradica-
tion requires combined innate and adaptive immune responses after
successful recognition of the malignant cells. Likewise, tumor growth
also relies on hematological cells to establish an immune-suppressive
TME. Therefore, both scenarios require immune cells to be recruited
[101]. This premise forms the main argument for using cells as drug
delivery vehicles. In addition, due to the ubiquitous nature of this ap-
proach, it has the potential to result in targeting strategies that are
widely applicable in cancer patients.
Like other drug carriers, cells can be used to protect their ther-
apeutic cargo from immune recognition and degradation, thereby
prolonging its circulation time [105]. In addition, the inherent migra-
tion capacity of immune cells can be used to specifically target in-
flammatory regions and the TME (Fig. 3). Even metastases can poten-
tially be targeted using this approach, since they are also associated
with increased immune cell infiltration [106]. Unlike the diffusion-
driven delivery used by other carriers (e.g. liposomes, synthetic poly-
mers and protein-DNA complexes), cells can truly actively penetrate
solid tumor tissues, even when they are characterized by high inter-
stitial pressure. Moreover, when DNA or RNA are used as launching
platforms for therapeutic proteins, such cellular carriers can effectively
be used as local production factories [105]. The possibilities of using
bioengineering tools to develop and iteratively improve molecular
sensors and switches further accentuates the advantages and future
potential of intelligent cell delivery vehicles [107–110].
5. Red blood cells
In theory, red blood cells (RBCs or erythrocytes) are ideal drug
carriers with the drugs either residing inside the RBCs or adsorbed to
their surface. These simple cells are readily available in vast quantities,
are very biocompatible even in allogeneic settings and are easily stored
[111]. RBCs have virtually unrestricted access to vascularized tissues
because of their relatively small size (7 μm diameter and 2 μm thick)
and capacity to deform (Table 1). In humans, they travel through the
circulatory system every 20 seconds and exhibit a lifespan of about 3–4
months in circulation while mouse RBCs have a lifespan of only 1
month [105,112–114]. Due to the lack of a nucleus, RBCs can be
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viewed as biological microparticles that can be used to compartmen-
talize drugs, e.g. to avoid renal clearance [14]. However, their size and
lack of migration machinery confines the use of RBCs to intravascular
applications such as circulating bioreactors for enzymes, as reservoirs
for slow drug release, as carriers for imaging agents and as “super-
carriers” for nanoparticles [14,113]. Alternatively, RBC precursors
(reticulocytes) contain translation machinery and can therefore be
exploited as production factories for mRNA-based therapeutics [115].
Some degree of targeting of the MPS is described e.g. via cell surface
modifications which mimic damaged or senescent RBCs [116,117].
Since a large portion of the MPS resides in the spleen and the liver, the
MPS-mediated clearance of RBC drug carriers is sometimes seen as
active targeting of these organs [111]. Nevertheless, since virtually all
circulating particles, debris and compromised cells are eventually
cleared by cells of the MPS, the added benefit of using RBCs for this goal
over liposomes can be questioned [118].
Most drug delivery strategies try to minimize RBC elimination
[113]. Apart from avoiding membrane alterations due to the drug
loading protocols, CD47 as a macrophage “do not eat me” signal or
complement inhibitory molecules can be introduced in the RBC
Fig. 3. Blood circulating cells as drug delivery vehicles. Non-immune cells such as reticulocytes, red blood cells and platelets can be used for intravascular release of
drugs but do not actively migrate to the interstitial space (green sector). Immune cells such as neutrophils, monocytes, NK cells and T cells traverse the blood (and
lymphatic) vessels before initiating transmigration into the TME and tumor tissue. The circulation time, the most distinctive properties and main chemoreceptors for
each cell type is depicted. RBC: red blood cells, MHC: major histocompatibility complex, TCR: T cell receptor, S1PR1: Sphingosine 1-phosphate receptor 1.
Table 1
Main properties of blood cells that have been considered as drug delivery vehicles.
Cell type Size (μm) Lifespan Main chemokine/receptor Remarks
RBC 6–7 3–4 months (Mouse: 1 month) - only for intravascular use, no nucleus, no activation
Platelet 1–3 9 days - Interesting for injuries involving hemostasis, no nucleus
Neutrophil 7–11 6–8 hours (t 1
2
) CXCL8/CXCR1–2 Widely applicable, rapid recruitment, collateral damage
Eosinophil 12–17 8–12 hours CCL11/CCR3a Collateral damage, allergens
Basophil 5–7 1–2 days CCL11/CCR3a Collateral damage, allergens
Monocytes 10–18 Ly6Chigh: 17 hours (t 1
2
)





Widely applicable, versatile functions, penetration into necrotic tumor core
React to ex vivo manipulation
T cell 8–10 2 weeks after activation PSGL-1/CXCR3 Local proliferation and memory cells, cytotoxic upon antigen recognition
NK cell 10 1 week CXCL8/CXCR1b MHC-independent cytotoxicity
a Eosinophils and basophils use very similar chemokine receptors but both cell types rely on specific combinations of receptors to achieve successful recruitment
into tissues and their main receptor CCR3 binds a large array of ligands [151].
b CXCR1 is an example of a chemokine receptor that can only be found on the cytotoxic NK cell subset.
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membrane. Moreover, RBC “immune-camouflaging” via PEGylation
offers some interesting prospects [113,119]. Accumulation of RBCs in
specific organs can be achieved by incorporating magnetic materials
into drug-loaded RBCs and subsequently applying an external magnetic
field on the organ of interest [120]. Similar strategies include the in-
duction of microvessel rupture through targeting microbubbles via ul-
trasound [121] or coating of the RBC surface with targeting moieties
such as antibodies [122]. However, since hydrodynamic forces drive
RBCs to the center of the vascular lumen and RBC-endothelial inter-
actions are minimized by the 0.5 μm thick endothelial glycocalyx
[123], the use of targeting moieties may not be efficient. It is currently
unclear how these approaches can be applied to situations where the
pathological region is unknown such as in metastatic disease.
Within the context of cancer therapy, RBC drug carriers can provide
the same benefits as liposomal drug formulations such as Doxil®, a
commercial PEGylated liposomal formulation of doxorubicin, but with
a decreased risk of mounting immune responses [124,125]. Interest-
ingly, although doxorubicin-loaded RBCs demonstrated virtually equal
tumor targeting compared to free doxorubicin, other differences in
biodistribution were noticed. Indeed, RBC-doxorubicin demonstrated
increased accumulation in the liver, the spleen and the lungs while free
doxorubicin resulted in a higher accumulation in the heart and skin of
tumor-bearing mice. Despite the prolonged release of doxorubicin from
the circulating RBCs that resulted in a significantly decreased tumor
volume, less cardiotoxicity and myelosuppression was seen [124].
Therefore, the effects of RBC-mediated drug delivery seem to be two-
fold: sustained release which maintains drug concentrations within the
therapeutic window and skewing biodistribution towards organs of the
MPS. However, a main limitation is that RBCs cannot be used to ac-
tively deliver drugs to extravascular targets.
6. Platelets
Platelets or thrombocytes are smaller (1–3 μm) than RBCs and only
circulate for about 9 days followed by their clearance via the MPS
[126]. They have a key role in blood clotting and secrete bioactive
molecules such as growth factors, chemokines, cytokines and matrix
metalloproteinases upon their activation. Moreover, they are also in-
volved in inflammation, wound healing and tumor progression
[126–128]. Activation takes place when circulating platelets encounter
damaged endothelial walls, where they change shape, shed off platelet
microparticles and aggregate to form clots through the interaction with
fibrin [129]. Pathological release of excessive platelet activators can
cause platelets aggregation within intact blood vessels or thrombosis
[126]. Like RBCs, platelets do not possess a nucleus and cannot actively
penetrate tissues. Nevertheless, their advantage as drug delivery ve-
hicles is that activation allows them to acquire more selectivity com-
pared to RBCs. As such, they can be used to selectively deliver ther-
apeutic cargo into platelet-activating tumors [130,131]. For example,
platelets have been loaded with doxorubicin to treat lymphoma-bearing
mice [132]. Similar to RBCs, this targeting strategy maintained the
tumor inhibiting effect of doxorubicin while avoiding its cardiotoxicity
[132,133]. Perhaps the most efficient strategy to utilize platelets for
drug delivery is post-surgical treatment because this medical inter-
vention is always associated with bleeding and hence, hemostasis. In
this context, a recent study demonstrated substantially increased anti-
PDL-1 efficacy through platelet-mediated drug delivery against residual
melanoma cells after surgical removal of the primary tumor [134,135].
Anti-PDL-1 antibodies were conjugated to the cell surface allowing
them to be dispersed on platelet-derived microparticles after activation
of the carrier platelets. This approach was also successfully demon-
strated after thermal ablation of the primary tumor [136].
7. Myeloid cells
Immune cells of the myeloid lineage mostly comprise cells involved
in the innate immune system (e.g. granulocytes, monocytes, macro-
phages, dendritic cells), but provide an essential bridge to the adaptive
immune system as well. They are implicated in all inflammation pro-
cesses and form important members of the TME. The modern view on
cell function incorporates a spectrum of functions ranging from immune
stimulatory to -suppressive, depending on the input the cell receives
[137]. In this regard, solid tumors frequently produce soluble factors
which favor the production and recruitment of (immature) myeloid
cells to the TME [138]. Paradoxally, these innate immune cells are
submerged in an array of tumor-derived factors, instructing them to
adopt phenotypes that are favorable for tumor survival, progression and
eventually metastasis [138]. Therefore, myeloid cells are essential
components in establishing an immunosuppressive TME reminiscent of
a state of chronic inflammation [139,140]. Due to the plastic nature of
myeloid cells in such an environment i.e. the ability to switch pheno-
types, much debate arises concerning their classification [141,142].
Most of these cells derive from circulating immune cells which were
recruited via the classic migration cascade. Of note, myeloid cells are
also suspected of shaping the “pre-metastatic niche”, indicating that
their recruitment can even precede the arrival of metastatic tumor cells
[143,144]. Besides the large amount of chemotaxins that recruit mul-
tiple immune cell populations, the occurrence of post-translationally
modified (e.g. glycosylation) chemokines in the TME was reported
[145,146]. These altered chemokines can demonstrate a change in re-
ceptor specificity and affinity, thereby selectively recruiting certain
leukocyte populations while dismissing others [147]. It is therefore
possible that additional selectivity can be obtained by focusing on those
populations that specifically react to these tumor-associated altered
chemokines. Given the high number of chemotaxins and corresponding
receptors involved in leukocyte recruitment, this will most likely re-
quire elaborate integrated analysis to predict their combined effect.
Still, myeloid cells have the inherent capacity of trafficking to solid
tumors. Those myeloid cell populations that have been reported as drug
delivery vehicles will be discussed below.
7.1. Granulocytes
Bone marrow-derived granulocytes are a group of innate immune
cells characterized by an irregular nucleus and the presence of granules
in their cytoplasm. They are typically further subdivided into 3 families:
neutrophils, eosinophils and basophils. Neutrophils have historically
been extensively studied due to their relative abundance i.e. 40–75% of
the total leukocyte count in human blood and their central role as “first
responders” in most inflammatory situations [148]. The vast amount of
available data on their biodistribution and migration properties pro-
vides us a template to which other immune cell populations can be
compared.
7.2. Neutrophils
In the bone marrow, granulocyte colony stimulating factor (G-CSF)
is the main stimulator of neutrophil differentiation, proliferation and
release [149]. Neutrophils (7–11 μm) are kept in the bone marrow
through the interaction with chemokine SDF-1, which is constitutively
expressed by bone marrow stromal cells. Binding of SDF-1 on neu-
trophil receptor CXCR4 then modulates integrin-ligand binding VLA-4/
VCAM-1 [150]. G-CSF inhibits this interaction by down-regulating the
expression of both SDF-1 and CXCR4, resulting in the release of neu-
trophils [149]. After leaving the bone marrow, neutrophils circulate in
the blood with a short half-life of only 6–8 hours. In the blood they
either slowly transit through intravascular “margination pools” such as
the liver, the spleen, the bone marrow and the lungs, get cleared from
the circulation or enter inflamed tissues [149,151]. About 50% of the
intravascular neutrophils will reversibly bind/roll along the en-
dothelium of postcapillary blood vessels [152–155]. This marginated
pool is in dynamic equilibrium with the circulating pool, a balance that
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can be manipulated to mobilize neutrophils back into circulation. Of
note, organ sequestration of cells also includes irreversibly bound cells,
trapped cells (e.g. by the MPS) and cells that migrated in the inter-
stitium [155]. Therefore, calculating the size of the marginated pool in
an organ is challenging, but most reports indicate that besides the liver,
especially the spleen and the bone marrow contain many of these
marginated neutrophils [155,156]. Moreover, a large portion of the
marginated neutrophils reside in the lungs, most likely due to the high
number of capillaries which all cells ejected from the heart have to
squeeze through [155,157–159]. Hence, increasing cardiac output via
e.g. adrenaline forces neutrophils into circulation [157,158].
Sequestration in a particular organ also depends strongly on the
maturation and activation status of the neutrophils [160]. The majority
of immature mouse neutrophils isolated from the bone marrow home
back to the bone marrow after infusion, but can later be redistributed to
sites of inflammation, while mature neutrophils localized equally be-
tween the liver and the bone marrow after injection, with no observed
remobilization to an inflammation site [160]. In fact, bone marrow can
act as a clearance organ for senescent neutrophils where they are
phagocytized by macrophages, which in turn produce G-CSF to stimu-
late the production and release of other neutrophils [156]. In contrast,
apoptotic neutrophils are mainly cleared by the liver Kupffer cells after
exposing phosphatidylserine on their cell surface [161]. Noteworthy,
inflammation-induced remobilization also causes neutrophils to accu-
mulate in the lungs, which sometimes leads to acute lung injury during
inflammatory states [162,163].
Activation of neutrophils occurs in 2 stages. Upon encountering
certain inflammation-associated factors (e.g. cytokines, chemokines,
bacterial and viral products), neutrophils are first ‘primed’ after which
they can demonstrate an enhanced activation by interaction with e.g.
pathogen- or damage-associated molecular patterns (PAMPs or DAMPs)
[151,164]. Priming induces cytoskeleton changes, making the neu-
trophils more rigid and consequently more prone to accumulating in
capillary beds [159,165,166]. It also induces many other phenotypic
changes, including adhesion to endothelium through increased ex-
pression and activation of β2 integrins, extravasation, increased re-
sponsiveness to chemokines (CXCL8 (IL-8) in particular) [167] and
resistance to apoptosis [164,168,169]. Thus, neutrophils that under-
went transendothelial migration are by definition primed [170]. In-
terestingly, circulating neutrophils can also be de-primed in the pul-
monary blood vessels by currently unknown mechanisms, and this
reversible activation state influences the kinetics and biodistribution of
neutrophils [166,169]. Thus, relatively nonresponsive neutrophils be-
come primed after encountering a first stimulus after which they be-
come fully activated upon encountering a second stimulus. This state is
characterized by phagocytic activity, degranulation and production of
neutrophil extracellular traps (NETs) [171].
Despite their abundance (50–70% of white blood cells in humans,
10–30% in mice), rapid recruitment and capacity to fight cancer cells
[172,173], neutrophils are rarely used as cell delivery vehicles because
of their reactive nature and short lifespan. Moreover, neutrophils are
notoriously known to cause substantial collateral damage to healthy
tissues after degranulation [174]. Nevertheless, to combat antibiotic
resistance, Wendel et al. (2015) devised an interesting strategy invol-
ving the encapsulation of chlorhexidine by dead bacteria used as stable
liposome-like drug carriers [175]. These bacteria were loaded into
neutrophils, infused in mice with liver abscesses and their subsequent
infiltration into the liver significantly reduced the bacterial burden.
Unfortunately, this study did not report biodistribution data. Moreover,
the absence of a chlorhexidine only-control prevents interpretation of
the added effect of using neutrophils as delivery vehicles. Such a control
was probably omitted from the study due to the toxic properties of this
topical antiseptic agent.
Overall, the short lifespan of neutrophils might enable to use these
innate immune cells as delivery vehicles in acute therapeutic settings,
provided that their off-target effects are genuinely restrained. In
addition, the concept of loading therapeutic agents (e.g. via nano-
particles) in immune cells within a patient is definitely worth pursuing
as it eliminates the need for collecting, isolating, loading and reinfusing
immune cells [176]. In this regard, Chu et al. (2017) demonstrated that
intravenously injected anti-CD11b-coated nanoparticles are taken up by
neutrophils which then accumulate in tumor tissue after induction of
acute inflammation [177]. In contrast, only low levels of accumulation
was seen upon injection of PEGylated nanoparticles or when no acute
inflammation was induced [177]. Similarly, neutrophils were used to
deliver paclitaxel-loaded liposomes to surgically resected gliomas
[178].
7.3. Eosinophils and basophils
After release from the bone marrow by IL-5, eosinophils (12–17 μm)
circulate only 8–12 hours in blood, where they comprise 1–3% of the
total leukocyte count and rely heavily upon CCR3 for their recruitment
into tissues(Table 1) [179,180]. Eosinophils have many homeostatic
functions, but can also be recruited in response to inflammation where
they are best known for their IL-5-mediated interactions with Th2
lymphocytes during parasitic infections and in response to allergens
[179]. Inflammation-induced degranulation of these cells is typically
associated with cell toxicities and disruption/remodeling of the ECM
[179]. They are also implicated in establishing the TME of solid tumors,
demonstrating their potential use as drug delivery vehicles [181]. Eo-
sinophil recruitment to tumors occurs in all stages of tumor growth and
independently from Th2 lymphocytes. Their accumulation is mainly
restricted to the fibrous tumor capsule and to areas of necrosis [182].
The capacity of adoptively transferred bone marrow-derived eosino-
phils to be efficiently recruited to inflammatory lungs upon allergen-
induction hints at a potential therapeutic use in this specific organ
[183]. However, it has been demonstrated that this type of inflamma-
tion is not restricted to eosinophils, but also recruits neutrophils and
lymphocytes [184].
Basophils (5–7 μm) represent the lowest fraction of leukocytes in the
blood (< 1%). They have an estimated lifespan of 1–2 days and are
mostly implicated in inflammation reactions associated with allergies
and parasites (Table 1) [180,185,186]. However, this stereotypical
view is currently discarded in favor of a complex immunomodulatory
and tissue remodeling function that is strongly dependent on its en-
vironment [185,187]. Their capacity to produce IL-4 and subsequently
elicit Th2 cell responses after adoptive transfer suggests therapeutic
potential of these cells to modulate immune responses [188]. Like eo-
sinophils, recruitment of basophils into tissues uses multiple chemokine
receptors and largely relies on the same chemokine receptors [189].
Eosinophils and basophils have not been explored as drug delivery
vehicles most likely due to their low presence in the blood, and hence
the problems associated with obtaining enough cells. Moreover, these
cells can potentially cause extensive tissue damage [182,186]. Never-
theless, since eosinophils and basophils are specialized cells implicated
in specific disease situations, they might have therapeutic potential in
future delivery strategies. Alternatively, parts of their migration ma-
chinery such as selected chemokine receptors could also be in-
corporated in other cells to acquire their specific tissue tropism.
7.4. Monocytes and macrophages
A population of self-maintaining tissue-resident macrophages and
classical dendritic cells (DCs) are established before birth. In addition,
bone marrow-derived cells of the monocytic lineage are continuously
produced to replenish and assist these cells in maintaining tissue in-
tegrity after birth [190,191]. The macrophage-DC precursor (MDP) or
monoblast, a common founder cell residing in the bone marrow, dif-
ferentiates into dedicated DC precursors and “common monocyte pro-
genitors” [192,193]. Monocyte development mostly relies on the in-
teraction of M-CSF or CSF1 with its receptor M-CSFR or CD115 and
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monocytes subsequently require CCR2 to exit the bone marrow
[194,195]. The postnatal bone marrow constitutes the main production
site of monocytes, but relocation of hematopoietic stem cells and pro-
genitor cells to the spleen can form supplementary sites of extra-
medullary hematopoiesis [196].
Monocytes represent about 10% of the circulating leukocytes in
human and 4% in mice. They comprise a highly dynamic cell popula-
tion that is vital in ensuring rapid injury detection, inflammation and
resolution. Like neutrophils, a substantial number of intravascular
monocytes can be found in marginal pools within organs such as the
lungs and the spleen [197,198]. Again, this marginated monocyte pool
is in dynamic equilibrium with circulating monocytes and can be mo-
bilized on demand [197,199]. Multiple monocyte populations are found
within the blood vessels. In mice, these populations can be dis-
criminated via their level of Ly6C expression, a cell surface marker
variably expressed by many immune cell populations except B cells
[200]. The Ly6Chigh (Gr-1+) monocytes also highly express the che-
mokine receptor CCR2 and are the first subset of monocytes to be re-
leased from the bone marrow [200]. Conversely, Ly6Clow monocytes
typically express the chemokine receptor CX3CR1 [201]. Cell surface
phenotyping consequently reveals two distinct mouse monocyte popu-
lations: “immature”, “classical” or “inflammatory” Ly6Chigh/
CX3CR1mid/CCR2+/CD62L+/CD43low monocytes, and “mature”, “pa-
trolling” or “resident” Ly6Clow(Gr-1-)/CX3CR1high/CCR2-/CD62L-/
CD43high monocytes (Table 2) [194]. The Ly6Chigh are termed “clas-
sical” because they typically enter inflamed tissues to further differ-
entiate into peripheral mononuclear phagocytes i.e. macrophages or
monocyte-derived DCs [194]. Of note, the murine Ly6Chigh monocyte
subset is considered to be the precursor of smaller Ly6Clow monocytes
through an intermediary Ly6Cint population [193,202]. Ly6Chigh
monocytes can even home back to the bone marrow before maturing
into Ly6Clow monocytes [203]. The latter can be seen as terminally
differentiated blood-resident macrophages that survey endothelial in-
tegrity, hence they are termed “patrolling” monocytes [190,194,202].
While the circulatory half-life of Ly6Chigh monocytes is estimated at
about 17 hours (Table 1), intravascular Ly6Clow monocytes exhibit far
longer half-lives ranging from 2 days up to 2 weeks [190].
Like their mobilization from the bone marrow, recruitment of
Ly6Chigh monocytes to sites of inflammation (including in the central
nervous system) is highly dependent upon the CCL2-CCR2 axis [204].
There, these inflammation-induced monocytes transiently assist the
self-maintaining pool of tissue macrophages [194]. Dependent on the
context of the microenvironment, monocyte-derived macrophages
subsequently polarize to a spectrum of cells between 2 opposing phe-
notypes: the classically-activated or pro-inflammatory “M1” macro-
phages versus the alternatively-activated or anti-inflammatory, tissue
repairing, “M2” macrophages [205]. It is currently unclear whether
some of these monocyte-derived macrophages can further establish in
the tissues through self-maintenance [194]. Nevertheless, it has been
demonstrated that tissue macrophages can proliferate at low levels
during steady-state and that their proliferative capacity is enhanced
through environmental cues such as IL-4 and M-CSF [206–208]. This
has also been observed for monocyte-derived macrophages in the gut
and in atherosclerotic plaques [209,210].
As mentioned earlier, to successfully migrate from the bone marrow
into inflamed tissues, Ly6Chigh monocytes rely on L-selectin-mediated
rolling and CCR2-mediated activation and chemotaxis based on CCL2
and CCL7 gradients [193,211–213]. In addition to these well-known
migration receptors, monocyte recruitment further involves many other
integrins and chemokine receptors such as CCR1 and CCR5, a com-
prehensive list is provided in the excellent review by Shi and Pamer
(2011) [214]. In contrast to these “inflammatory” Ly6Chigh monocytes,
Ly6Clow monocytes do not express L-selectin nor CCR2 but primarily
rely on CX3CR1 and β2-integrins such as LFA-1 which engage with
endothelial ICAMs [193,213]. Instead of rapidly rolling, steady state
Ly6Clow monocytes continuously “crawl” over relatively long distances
on the luminal side of mouse blood vessels i.e. at about 12 μm/min,
independent of blood flow direction [193]. Interestingly, the ideal lo-
cation of Ly6Clow monocytes makes them swiftly (< 1 hour) extra-
vasate into tissues upon induction of inflammatory stimuli, a response
found to precede that of neutrophils [193].
Intravenous injection of mouse macrophages results in a typical
distribution pattern [215]. This pattern is characterized by rapid dis-
appearance from the circulating pool with an initial arrest in the lungs,
followed by redistribution to mainly the spleen and the liver [215,216].
When a distant site of inflammation is present e.g. in the footpad,
specific accumulation of a small portion of the injected macrophages is
observed for at least 1 week [216]. Bromodeoxyuridine labeling de-
monstrated that Ly6Chigh monocytes take 2–3 days to fully accumulate
in tumor tissue after arriving in the circulation [217].
Due to their well-known ability to kill tumor cells, their antigen-
presenting properties and their accumulation in necrotic/hypoxic re-
gions of solid tumors, classically activated (by IFN-γ and/or LPS)
macrophages were explored as cancer treatment already in the 1990s
[110,218,219]. Proper macrophage culture upscaling techniques were
even developed to facilitate their clinical use in humans [218]. Indeed,
the natural tendency of macrophages to be attracted to hypoxic regions
in tumors presented an opportunity to target these hard-to-access areas
frequently associated with resistance to chemo- and radiotherapy
[220,221]. Moreover, injected macrophages had previously been
shown to enter small lung metastases of B16 melanoma [222]. More
recently, intraperitoneal injected macrophages were found to traffic
into an experimentally-induced inflamed pancreas, indicating their
potential use in a broad range of inflammation-associated pathologies
[223]. The latter experiment also indirectly demonstrated that organs
in the abdominal cavity are likely to be targeted with much higher
efficiency after intraperitoneal injection compared to systemic injection
[223]. However, since similar inflammation site-targeting efficiencies
can be achieved with macrophage cell lines such as the mouse
RAW264.7 as opposed to primary macrophages, a rather non-selective
accumulation is to be suspected [224].
In the context of gene therapy, macrophages can be transduced with
viral vectors coding for prodrug-activating enzymes. Additional layers
of selectivity can be obtained by incorporating hypoxia response ele-
ments (HRE), driven by transcription factors such as hypoxia-inducible
factors [225,226]. The in vivo validation of obtaining increased se-
lectivity by combining HRE with therapeutic genes stalled about 20
years ago, but is still worth exploring since the clinical efficacy of
systemic macrophage-based cell therapies turned out to be limited,
despite being well-tolerated [218,227]. The potential of multi-layered
selectivity using tumor-homing macrophages as vehicles has been de-
scribed for a hypoxia-regulated oncolytic adenovirus, whose prolifera-
tion is additionally restricted to prostate tumor cells by prostate-specific
promoter elements [228]. When the criteria are met, local amplification
of the viral agents can then compensate for the low number of trans-
duced cells that were able to reach the target site [229]. Additional
therapeutic efficiency can be obtained when cell-delivered oncolytic
virus therapy is initiated directly after tumor radiation therapy
Table 2
Commonly used cell surface markers of mouse and human blood cells.
Cell type Mouse Human
RBC CD235a, TER-119 CD235a
Platelet CD41, CD62Pa CD42b, CD62Pa
Neutrophil CD11b, Ly6G CD15, CD16, CD66b, MPO
Eosinophil CD11b, Siglec-F CD11b, Siglec-8
Basophil CD200R3 CD123
Monocytes CD11b, CD115, Ly6C, CCR2, CD62L CD14, CD16, CD64
T cell CD3, CD25a, CD69a CD3, CD25a, CD69a
NK cell CD3(-), CD11b, CD27 CD3(-), CD56, CD16
a These markers are only present after cell activation.
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[230,231]. Unfortunately, no data on the biodistribution of these vec-
tors in organs other than the prostate tumor were included [228]. Of
note, systemically administered oncolytic viruses are impeded by the
same barriers as nanoparticles, e.g. interaction with blood cells, com-
promised access to non-vascularized regions within the tumor, dense
collagen deposition and elevated interstitial pressure [232].
Summarized, much is known about ex vivo culture of primary
monocytes. Employing this versatile cell type as drug delivery vehicles
is tempting because they are involved in many pathologies and are well-
tolerated after administration. Furthermore, the ability of monocytes to
traffic deep into badly perfused tumors makes them appealing in these
settings as well. However, monocytes are hardwired to react heavily to
foreign substances and can therefore be difficult to manipulate for
therapeutic purposes.
7.5. Myeloid-derived suppressor cells
Tumor-associated soluble factors induce and release immature im-
mune cells of myeloid lineage from the bone marrow. These cells cause
immunosuppression in the TME and are therefore named myeloid-de-
rived suppressor cells (MDSCs) [233,234]. They constitute a hetero-
geneous population that can be broadly subdivided into polymorpho-
nuclear (PMN-MDSC) and monocytic (M-MDSC) subsets. However,
solely based on immunophenotypic markers, MDSCs are difficult to
distinguish from their more mature counterparts and therefore require
functional evaluation of their immature and immunosuppressive nature
[233,235,236]. Interpretation of the already vague distinction between
MDSC and mature myeloid cells is further complicated by non-stan-
dardized methods of MDSC isolation and storage [237,238]. Further-
more, MDSCs can differentiate into mature myeloid cells and vice versa
within the TME [239]. Nevertheless, atypical myeloid subsets with
distinct properties such as decreased cellular density have been clearly
identified in cancer patients [240].
In tumor-bearing mice, a highly increased number of mostly PMN-
MDSCs are mobilized from the bone marrow and accumulate in organs
such as the lungs, the liver and the spleen [241]. The latter represents
an important organ in myeloid cell dissemination and even forms a
major site of extramedullary hematopoiesis in some cancer models.
Splenectomy delays tumor growth by reducing aberrant myeloid cell
responses in the blood and tumor tissues [242,243]. Adoptively trans-
ferred MDSCs traversed the lung and liver capillary networks more
rapidly in tumor-bearing mice than in healthy control mice and sub-
sequently massively accumulated in the spleen [241]. In addition,
tumor-bearing mice supported MDSC survival, decreased their sus-
ceptibility to apoptosis and stimulated their proliferation in the spleen
[241]. Hypothetically, tumor-associated factors inhibit the expression
of apoptotic markers on adoptively transferred MDSCs and conse-
quently prevent their sequestration in organs associated with cell
clearance.
The increased production, survival and mobilization of MDSCs re-
sults in more circulating and recruited cells into the tumor via a mul-
titude of chemokines, cytokines and mediators of inflammation [244].
Interestingly, increased blood PMN-MDSCs do not always correlate
with increased numbers in the TME due to impaired migration func-
tions resulting from e.g. downregulation of chemokine receptors CXCR1
and CXCR2 [240]. Conversely, the highly CXCR2-dependent recruit-
ment of PMN-MDSCs into the TME can be blocked either by monoclonal
antibodies [245] or by small molecule inhibitors [246]. Utilizing such
inhibitors leads to improved therapeutic outcomes when combined
with anti-PD-1 treatment, anti-CTLA-4 treatment or adoptive transfer of
T cells [246,247].
Bone marrow-derived MDSCs can be generated in vitro via GM-CSF
and IL-6 supplementation to standard culture medium [248]. This
method was used to investigate the biodistribution of adoptively
transferred PMN-MDSCs in an orthotopic PyMT-MMTV mammary
tumor mouse model [249]. Intravenously injected DiD-labeled PMN-
MDSCs mostly accumulated in the liver, the spleen and the lungs but
fluorescence was also observed at the primary tumor, both at 48 hours
and at 7 days after injection [249]. Moreover, injected MDSCs also co-
localized with tumor metastases in the adrenal gland but off-target
splenic accumulation was seen as well [249]. However, histological
verification should be performed to evaluate whether this acquired
fluorescence originated from intact labeled MDSCs [249,250].
The tumor homing tendency of mouse Ly6C+ MDSCs has been
exploited to more efficiently deliver oncolytic viruses into the TME
[251]. However, this study used an intrahepatic tumor model in which
the obtained “tumor-specific” MDSCs are likely confounded with
MDSCs residing in the liver. Another study reported delivery of atte-
nuated Listeria monocytogenes bacteria engineered to express tumor
antigens via MDSCs into mouse primary tumors and metastases [252].
In addition to their ability to elicit antigenic responses, these bacteria
infect and kill tumor cells as well [253]. Despite infecting both MDSC
populations, bacterial proliferation and subsequent delivery of L.
monocytogenes occurred mostly via M-MDSCs and resulted in equally
efficient delivery at the primary tumor and tissue metastases of both
young and old mice. In contrast, a much lower bacterial load was de-
monstrated in the spleen [252] although assessing the contribution of
the MDSC as vehicles is difficult since much of the selectivity might be
related to the bacteria alone.
In conclusion, it remains unclear whether MDSCs demonstrate
higher tumor recruitment potential compared to mature myeloid cells.
Further studies are needed to answer this question and to unravel how
the migration of MDSCs differs from other immune cell populations.
8. T cells
The trafficking properties of T cells are currently intensely in-
vestigated due to their potent capacity to eradicate tumor cells, cer-
tainly since the availability of clinically applicable methods to geneti-
cally engineer CTLs that are able to kill cells expressing an antigen of
choice [254,255]. Some of the specific properties of lymphocytes in
relation to myeloid cell trafficking will be summarized (Table 1), for
more detailed information readers are kindly referred to the excellent
up-to-date reviews on this subject [62,256–259].
Cells of the adaptive immune system show some remarkable dif-
ferences with innate immune cells. T cells develop in the thymus in-
stead of the bone marrow, enter the circulation in a “naive” state and
require multistep activation to initiate their effector functions.
Moreover, they have the capacity to proliferate upon activation thus
amplifying their immunological contribution and to produce long-
lasting memory cells. Importantly, this property is exploited to acquire
sufficient cells for T cell-based therapies [260]. In further contrast to
myeloid cells, naive T cells mainly traffic through lymphoid tissues via
L-selectin and CCR7-mediated interactions with corresponding ligands
i.e. PNAd and CCL19/21, respectively, on specialized high endothelial
venules in lymph nodes [261]. Once activated in these lymphoid tis-
sues, T lymphocytes downregulate their surface expression of CCR7,
egress the lymph node via their sphingosine 1 phosphate receptor 1 and
upregulate other adhesion receptors to acquire the capacity to migrate
into non-lymphoid tissues [56,62]. Interestingly, these newly expressed
adhesion receptors partly differ depending on the tissue location of the
priming lymph node and antigen-presenting dendritic cells, thereby
bestowing a certain vascular “ZIP code” on the activated T lymphocyte.
This combination of acquired adhesion receptors/ligands corresponds
to adhesion ligands/receptors in the tissue where the priming occurred
[62,256]. Consequently, eliciting adaptive immunity through vaccina-
tion preferentially occurs in the targeted tissue. Some homing re-
ceptors/ligands such as CXCR3 and PSGL-1 are upregulated in-
dependent of the activation site and inflammation utilizes many of the
homing receptors/ligands normally restricted to specific tissues in
steady state conditions [256]. This inflammation-induced upregulation
of chemokines and vascular receptors is often actively inhibited (e.g. by
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VEGF) in solid tumors, but can be reinitiated by experimentally in-
troducing stimulators of inflammation such as Toll-like receptor (TLR)-
agonists [256,262,263].
Aberrant tumor blood vessel morphology also contributes to de-
fective T cell homing. In this regard, low-dose anti-angiogenic therapy
might be more beneficial in treating solid tumors than high-dose
therapies as the former allows normalization of the tumor vasculature
which allow more efficient recruitment, adhesion and extravasation of
T cells [48]. In addition to normalizing the tumor vasculature, tumor-
matching chemokine receptors such as CXCR2 [264], CX3CR1 [265],
CCR4 [266] and CCR2 can all be genetically introduced into T cells
[257,267,268]. Unfortunately, clinical studies with therapeutic T cells
have indicated that addition of these chemokine receptors only mod-
estly improved the infiltration in humans [257]. Yet, an interesting link
between myeloid cells and lymphocyte recruitment was recently de-
monstrated: infiltration of immunosuppressive PMN-MDSCs in mouse
tumors was substantially reduced upon administration of a small mo-
lecule inhibitor of both CXCR1 and CXCR2 [246]. In turn, this greatly
enhanced T cell accumulation in these tumors, indicating that myeloid
cells residing in the TME contribute to constraining lymphocyte re-
cruitment.
Chimeric antigen receptors (CARs) were originally engineered to
confer selective T cell-mediated killing of target cells bearing the an-
tigen of choice independent of MHC. However, the same principle can
be used to elicit expression of a certain gene of choice after recognition
of the antigen. In essence, this makes CAR T cells drug delivery vehicles
for therapeutic genes such as cytokines and they are therefore termed
“T cells redirected for universal cytokine killing” (TRUCKs) [269]. For
example, TRUCKs can be used to locally express IL-12 after recognition
of its cognate antigen [270]. Indeed, this is a very elegant system be-
cause IL-12 is a cytokine that elicits potent Th1 cellular immune re-
sponses but cannot be administered systemically due to unacceptable
toxicity [271]. Its expression can be linked to either CAR or TCR acti-
vation through incorporation of a nuclear-factor of activated T cells
(NFAT) minimal promoter [269]. Due to the proliferative property of T
cells, TRUCKs which constitutively express IL-12 can also be con-
structed [272]. Systemic injection of a small number of such IL-12
TRUCKs will not elicit toxic effects [273]. However, after encountering
the targeted cells, T cells massively proliferate and exponentially in-
crease local IL-12 concentrations until therapeutic effects are achieved
[272]. Nevertheless, induced expression of IL-12 is considered more
safe than constitutively expressed IL-12 [269]. Cytotoxic T cells can
also be used to deliver drugs adsorbed to their surface. For example,
Jones et al. (2016) conjugated drug-loaded lipid nanoparticles to the
surface of T cells [274]. Upon recognition of their cognate antigen, the
T cells secrete perforins which not only lyse the target cells but also
release the drug from the adsorbed lipid nanoparticles. The drawback of
CAR or TCR-mediated release is that it requires prior knowledge on the
targeted antigen. Choosing the wrong antigen can result in severe “on-
target off-tumor” side effects. Moreover, targeting a single antigen is
often insufficient in constantly evolving heterogeneous pathologies
such as cancer [56,256]. Alternatively, more stable TME-associated
antigens such as VEGFR-2 can be targeted as well [275].
The development of multiple generations of CAR T cells have pro-
vided extensive insight into the possibilities of genetic engineering. In
fact, CARs have also been inserted in other cell types [276]. Facilitated
by gene-editing technology, researchers are exploring genetic knock-
out of MHC-associated genes to prevent host immune recognition of
adoptively transferred cells [277,278]. A complementary strategy is to
remove native T cell receptors from CAR T cells to prevent graft versus
host reactions. Consequently, allogeneic cells can be used to create “off
the shelf” cell delivery vehicles.
9. Natural killer cells
Treating tumors with bioengineered CAR T cells requires sufficient
functional T cells to reach the tumor. This poses a problem in treating
immunosuppressive tumors or “cold tumors”, in which T cells cannot
permeate [279]. Natural killer (NK) cells are currently explored to
overcome some of the limitations associated with T cells [280]. TCR/
CD3-negative NK cells are lymphocytes which possess essential func-
tions for the innate immune system. This makes NK cells interesting for
cancer immunotherapy [281]. Their cytotoxic effector mechanisms in-
clude perforin/granzyme-containing granules, antibody-dependent cell-
mediated cytotoxicity (via FcγRIII or CD16) and cell death through
death-receptor and interferon-γ mediated pathways [282]. Through
both activating and inhibitory receptors, they can recognize target cells
based on reduced expression of inhibitory ligands and/or increased
expression of activating ligands and thus exert broad and rapid cyto-
toxicity against e.g. virus-infected cells or tumor cells [283]. For ex-
ample, loss of MHC class I molecules (inhibitory signal) and/or in-
creased expression of stress ligands such as MICA, MICB and ULBPs
(activating signal) makes cells susceptible to NK cell-mediated lysis
[283].
Fueled by the success of CAR T cells, NK cells are now also ge-
netically modified with CARs [284]. In essence, this makes CAR-NK
cells function as adaptive immune cells via their tumor antigen-re-
cognizing CAR and as innate immune cells through their native re-
ceptors. This combination makes tumor escape through downregulation
of CAR targets less likely. Moreover, no cytokine release syndrome is
expected since NK cells do not proliferate upon stimulation [285].
Importantly, because NK cell-mediated cytotoxicity is MHC-in-
dependent, they lack the potential to cause graft-versus-host disease,
which allows NK cells to be used as off-the-shelf allogeneic therapeutics
[283].
Whereas all lymphoid and non-lymphoid tissues contain NK cells,
most human NK cells in the lymph nodes are of the immature
CD56bright/CD16low/perforin- subset and about 90% of the NK cells
found in the blood and the spleen are of the more mature cytolytic
CD56dim/CD16+/perforin+ subset(Table 2) [282,286]. The non-cyto-
toxic CD56bright and cytotoxic CD56dim NK cell subsets are also char-
acterized by a different set of chemokine receptors [287,288]. In mice,
the functional classification occurs through CD27/CD11b character-
ization. Immature mouse NK cells are double negative CD27-/CD11b-.
Next, they mature into CD27+/CD11b- to CD27+/CD11b+ and fi-
nally CD27-/CD11b+ NK cell subsets [289].
In vitro cultivation of primary NK cells is technically challenging.
Current strategies therefore rely on infusing irradiated NK cells from the
human NK-92 cell line which retain their cytotoxicity but exhibit sup-
pressed proliferation to prevent their permanent engraftment [283]. As
a result, CAR-NK-92 cells remain in circulation for about 48 hours
[290] and are no longer detectable within 7 days of adoptive infusion
(Table 1) [291]. Alternatively, human embryonic stem cells [292] or
CAR-NK cells derived from induced pluripotent stem cells demonstrate
equal anti-tumor capacities as CAR T cells, but with a better safety
profile [293,294]. Of note, activating the NK cells prior to adoptive
transfer significantly improves their tumor trafficking in mice 1 hour
after administration but also causes them to accumulate in off-target
organs such as the lungs, the liver and the spleen [282]. Such activated
NK cells also demonstrate accumulation at pulmonary metastases. This
interesting property of NK cells was used to deliver membrane-linked
doxorubicin to B16 melanoma metastases in the lung thereby severely
concentrating doxorubicin at these sites [295].
10. Employing nanoparticles to load tumor-targeting immune
cells
The focus of cell-based drug delivery is gradually merging with the
field of nanoparticles [296]. Careful nanoparticle design considerably
improves drug pharmacokinetics, but still lacks efficient targeting ca-
pacity. However, when combined with the inherent properties of im-
mune cells to target inflamed regions, a marked increase in delivery
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efficiency has been reported [148]. For example, in a recent study
Ly6Chigh monocytes loaded with paclitaxel-containing pH-sensitive
micelles demonstrated increased paclitaxel accumulation in the pri-
mary tumor and pulmonary metastases when compared to micelles
directly injected in the blood [297]. Moreover, about one decade ago
macrophages loaded with nanoparticles containing an antiviral drug
severely prolonged drug release and brain deposit in an HIV-1 en-
cephalitis mouse model [298]. However, ex vivo culture of monocytes
and loading them with nanoparticles or reporter genes can negatively
impact the delivery efficiency of these cells [299].
Another example is to coat nanoparticles with anti-CD11b to target
circulating myeloid cells. After inducing an acute inflammation reac-
tion in the TME by photosensitization therapy, neutrophils that have
taken up these anti-CD11b nanoparticles are recruited into the TME
[300]. Moreover, since neutrophil infiltration has been observed after
radiation therapy it can complement this frequently used cancer
treatment modality [301]. Although this strategy resulted in higher
delivery of nanoparticles in the TME, radiation therapy still requires
knowledge about the exact position of the TME and hence, is not
practical for targeting metastases of unknown locations. Nevertheless,
systemic immunotherapy using antibodies directed against melanoma
antigens is also associated with neutrophil influx and could therefore
benefit from this approach as well [302]. Still, two additional problems
arise when employing immune cells to deliver therapeutic nano-
particles on site: [1] drug leakage from the nanoparticle into the im-
mune cell can compromise its function and viability, [2] immune cell
recruitment inevitably results in excessive drug deposition into se-
questration organs such as the lungs, the liver and the spleen [303].
For example, in a recent study Ly6Chigh monocytes loaded with
paclitaxel-containing pH-sensitive micelles demonstrated increased
paclitaxel accumulation in the primary tumor and pulmonary metas-
tases when compared to micelles directly injected in the blood [297].
Moreover, about one decade ago macrophages loaded with nano-
particles containing an antiviral drug severely prolonged drug release
and brain deposit in an HIV-1 encephalitis mouse model [298]. How-
ever, ex vivo culture of monocytes and loading them with nanoparticles
or reporter genes can negatively impact the delivery efficiency of these
cells [299].
Multiple strategies have been described to load cells with synthetic
or biological therapeutic agents. For example, enzymes can be en-
capsulated into red blood cells via hypotonic dialysis and isotonic re-
sealing [304] or can be attached to cell membranes via integration of
biotin-phospholipid integration followed by binding of avidin-con-
jugated agents [305]. Alternatively, cell-penetrating peptides are used
to facilitate intracellular delivery of hydrophilic agents or macro-
molecular substances [306]. Of particular interest is the use of nano-
particle drug carriers which can be coated with cell membranes
[307,308] or attached/loaded into the cellular vehicles. Membrane
coating transfers beneficial properties of the source cells (e.g. targeting
ligands/receptors and “don't-eat-me” signals) to the used nanoparticles.
This strategy is covered in the review by Zhang et al. (2019) [309].
Attaching nanoparticles to endogenous circulating cells is known as
“cellular hitchhiking” [310] and can be achieved by non-covalent ad-
sorption via hydrophobic, electrostatic, Van der Waals or hydrogen
bonding [310,311]. In addition, drug carriers can be attached to cells
via receptor-ligand interactions [312] or they can even be covalently
attached to functional thiol [313] or amine [314] residues on the cell
surface [315]. Internalization of adherent nanoparticles through en-
docytosis, pinocytosis or phagocytosis is considered a limiting factor
but can also be used to load therapeutic cargo in phagocytes [315,316].
However, the latter approach requires proper protection against in-
tracellular degradation mechanisms.
11. Challenges and future perspectives
11.1. The lungs, the liver and the spleen
To scout the entire organism for possible target sites such as cancer
metastases, systemic administration is mandatory, but also obligates the
injected cells to pass through certain checkpoints. Typically, the lungs
are the first checkpoint encountered after intravenous injection [303].
Priming or activation of immune cells leads to cytoskeleton re-
arrangements which makes them more rigid and exhibit a higher ten-
dency to get stuck into capillary beds such as in the lungs
[159,165,166,317]. Likewise, a clear size-dependent pulmonary accu-
mulation of intravenously injected nanoparticles has been described in
rats [318,319]. Simultaneous treatment with vasodilation agents such
as sodium nitroprusside helps cells to pass through the lungs more ra-
pidly, further indicating that physical obstruction is at least partly re-
sponsible for the pulmonary retention of injected immune cells
[320,321]. After their release from the lungs, systemically injected cells
are distributed among all other organs.
The two main sites of subsequent sequestration are the liver and the
spleen [303,322–324]. It is difficult to assess what exactly happens to
the immune cells in these two organs and whether the observed re-
tention in these secondary “checkpoints” is reversible. One possibility is
that the immune cells accumulate for mere physical reasons (e.g. large
vascular volume of these organs or small capillary diameters) [325].
Given that spleen contraction is susceptible to α-adrenoceptor agonists,
treatment with adrenaline or epinephrine can possibly elicit leukocyte
mobilization from this reservoir [326]. Although spleen contraction
substantially increases blood hematocrit in horses and dogs, it appears
to be far less influential in humans [327]. Nonetheless, catecholamine-
mediated demargination combined with expulsion of splenic leukocytes
likely contributes to increased circulation of adoptively transferred
immune cells [157,158,326]. Moreover, immune cell mobilization can
readily be enhanced through exercise, which increases immune cell
infiltration in tumors and subsequent therapeutic effect [257]. Re-
moving the spleen before injection of immune cells resulted in in-
creased liver accumulation of these cells, but their short-term traf-
ficking to tumors remained unaffected [328]. This key observation
could indicate that the luminal surface of the tumor vasculature is sa-
turated with endogenous immune cells, hindering injected cells to find
an available attachment site [329]. Consequently, intratumoral cell
accumulation is a gradual process that requires multiple days or even
weeks to complete.
Another possibility is that injected immune cells are actively ar-
rested by other cells. The removal of dead or compromised cells from
circulation (efferocytosis) by cells of the MPS is a major function of both
the spleen and the liver [330]. Any deviation of the cell surface caused
by experimental manipulations such as isolation, ex vivo culture,
transfection and labeling likely activates markers of efferocytosis. This
is exemplified by the rapid disappearance of optimally stored red blood
cells (RBCs) after transfusion [331]. In addition, other “eat me” signals
such as phosphatidylserine externalization, changes in either charge or
glycosylation patterns, ICAM-1 alterations and exposure of calreticulin
on the cell surface all mark a cell for phagocytosis by the MPS [332].
Interestingly, masking phosphatidylserine exposure via annexin V pre-
vented subsequent phagocytosis and could therefore be explored as a
way to decrease the arrest of adoptively transferred immune cells in
organs participating in efferocytosis [333]. Our group has recently
demonstrated that depleting the MPS via pretreatment with clodronate
liposomes drastically increased both the circulatory half-life and tissue
accumulation efficiency of infused bone marrow-derived monocytes
[329]. In addition, no change in monocyte distribution pattern was
observed after depletion of endogenous neutrophils [329]. Alternative
strategies could consist of depleting cells that express apoptotic markers
before their infusion, or to incorporate cell surface “don't eat me” sig-
nals such as CD47 into the cellular vehicles [334]. In addition, adding
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anti-apoptotic agents to the culture medium can perhaps diminish the
fraction of injected cells that express apoptotic markers [335]. Com-
pared to RBCs, decorating the cell surface with polyethylene glycol
(PEGylation) is likely less efficacious on immune cells as these mod-
ifications have been shown to interfere with surface molecules. Hence,
PEGylation will likely inhibit the migration cascade of immune cells
[113].
11.2. Prolonging the circulatory half-life of immune cells as the first
pillar
Despite the preference for recruiting certain immune cell types to
the TME in the long-term, the short-term accumulation of injected
immune cells is mainly of non-specific nature [303,328]. Retention of
injected immune cells therefore likely depends primarily on physical
properties such as tumor perfusion, total tumor blood volume and cell
flow rate. This underscores the importance of optimizing essential
physical properties such as the circulatory half-life rather than identi-
fying optimal injection sites [336]. Nevertheless, the rapid recruitment
of endogenous neutrophils in acute inflammatory contexts suggests that
some level of short-term trafficking of specific immune cell subsets is
possible but we should bear in mind the high number of circulating
neutrophils in steady-state conditions [337] and the induced reactive
neutrophilia in inflammatory conditions which further helps circulating
neutrophils to accumulate at the pathological site by ensuring their
constant passage [338].
Considering these general remarks, prolonging the circulatory half-
life of cell vehicles should be designated as the first pillar in this re-
search field and preventing the immediate recognition of altered cell
surfaces should be prioritized in future research endeavors (Fig. 4).
Even when injected cells are not immediately sequestered in organs
such as lungs, spleen and liver, only a small portion of them will ac-
tually travel through the blood vessels of their targets sites. Moreover,
interaction with the endothelium through rolling, adhesion and trans-
migration is only reserved for a minority of passing cells and thus, the
majority of the cellular vehicles will return to the heart and the lungs to
restart the cycle. Therefore, like passively flowing particles, these in-
jected cells also largely depend on their circulatory half-life to increase
their chances of successfully engaging the adhesion cascade at their
target sites.
Based on the demargination and consequential leukocytosis medi-
ated by glucocorticosteroid administration, it would perhaps be inter-
esting to further investigate whether glucocorticosteroids can also in-
crease the circulatory half-life of adoptively transferred immune cells
[339–342]. Moreover, this class of anti-inflammatory and strongly
immunomodulating drugs also prevents apoptosis of neutrophils and
can potentially inhibit delayed adaptive immune responses against
therapeutic transgenes [343]. Despite the existence of a vascular ZIP-
code system for primed effector T cells, specific tissue migration is
likely hampered by the shared expression of adhesion molecules in
different organs [62]. Therefore, instead of trying to acquire increased
specificity via addition of adhesion receptors in cellular vehicles, it
would perhaps be more efficient to mask the non-specific receptors/
ligands already present on these cells. This would then substantially
decrease interaction with adhesion receptors in non-targeted organs
and possibly increase circulation half-life and target site accumulation
of the injected cells.
One of the many exciting evolutions of the past decade is the mer-
ging of the nanoparticle delivery field with research on immune cell
trafficking [148,300,302,344,345]. The main strategy is to bestow
immune cell-targeting properties to nanoparticles containing a ther-
apeutic agent. After systemic injection, circulating immune cells then
adsorb or engulf the nanoparticles, effectively guiding them into dis-
eased tissues such as solid tumors. Given that leakage from the nano-
particles can be constrained, “piggybacking” endogenous immune cells
can potentially bypass the clearance problems associated with ex vivo
manipulations.
11.3. Conditional release as the second pillar
Even if we assume that the hurdles of efferocytosis and circulatory
half-life could be adequately addressed, unwanted off-target accumu-
lation by physical means such as differences in total vascular volume
between organs, will always hamper drug delivery efficiency. By taking
advantage of the many possibilities that cells offer for genetically en-
gineering multilayered selectivity, investing substantial research efforts
into developing tools for conditional release should form the second
pillar of obtaining true targeted delivery (Fig. 4). Currently pursued
Fig. 4. Future perspectives on using immune cells as targeted drug delivery vehicles. As a first pillar for future research endeavors, we propose increasing the
circulatory half-life of cellular carriers to improve non-specific tumor accumulation. As a second pillar, conditional release mechanisms should be developed which
release the drug from its carrier based on specific cues in the tumor.
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avenues include local amplification of adoptively transferred T cells
after recognition of their cognate antigen [346], local amplification of
oncolytic viruses [347] and development of genetic switches [348–350]
that control transgene expression based on environmental cues. In our
opinion, the development of multilayered genetic switches has the most
potential in terms of flexibility (i.e. back-and-forth optimization and
adaptation). These switches do not necessarily require prior knowledge
about a specific antigen, but can link cell phenotypic changes based on
environmental cues in the TME with the conditional expression of a
therapeutic transgene. For example, combining a miRNA-driven ap-
proach [351] with other selective expression techniques such as po-
larization-dependent promoters [352] or enhancers [353] can un-
doubtedly ensure specific transgene expression in targeted tissues. In
this regard, integrating hypoxia responsive elements (HREs) in the ge-
netic constructs can confine transgene expression to the badly perfused
tumor regions [225,226]. Nevertheless, these HREs could also impose
too much restrictions (e.g. early metastatic sites do not necessarily
contain hypoxic regions) and therefore limit the therapeutic relevance
of this construct.
Acknowledgements
The authors acknowledge funding from the Research Foundation -
Flanders (1119318N, G087516N) and the Special Research Fund from
Ghent University (BOF15/GOA/013).
References
[1] A. Skuse, Wellcome Trust-Funded Monographs and Book Chapters. Constructions
of Cancer in Early Modern England: Ravenous Natures, Palgrave Macmillan (c)
Alanna Skuse 2015, Basingstoke (UK), 2015.
[2] W. Zhang, P. Huang, Cancer-stromal interactions: role in cell survival, metabolism
and drug sensitivity, Cancer Biol. Ther. 11 (2) (2011) 150–156.
[3] M. Arruebo, et al., Assessment of the evolution of cancer treatment therapies,
Cancers 3 (3) (2011) 3279–3330.
[4] S.A. Abraham, et al., The liposomal formulation of doxorubicin, Methods Enzymol.
391 (2005) 71–97.
[5] G. Kohler, C. Milstein, Continuous cultures of fused cells secreting antibody of
predefined specificity, Nature 256 (5517) (1975) 495–497.
[6] Y.H. Yun, B.K. Lee, K. Park, Controlled drug delivery: historical perspective for the
next generation, J. Control. Release 219 (2015) 2–7.
[7] C.N. Simonti, J.A. Capra, The evolution of the human genome, Curr. Opin. Genet.
Dev. 35 (2015) 9–15.
[8] D.S. Krause, R.A. Van Etten, Tyrosine kinases as targets for cancer therapy, N.
Engl. J. Med. 353 (2) (2005) 172–187.
[9] J. Sleeman, P.S. Steeg, Cancer metastasis as a therapeutic target, Eur. J. Cancer
(Oxford, England : 1990) 46 (7) (2010) 1177–1180.
[10] S.A. Eccles, D.R. Welch, Metastasis: recent discoveries and novel treatment stra-
tegies, Lancet (London, England) 369 (9574) (2007) 1742–1757.
[11] K.W. Hunter, R. Amin, S. Deasy, N.H. Ha, L. Wakefield, Genetic insights into the
morass of metastatic heterogeneity, Nat. Rev. Cancer 18 (4) (2018) 211–223.
[12] B. Meibohm, H. Derendorf, Basic concepts of pharmacokinetic/pharmacodynamic
(PK/PD) modelling, Int. J. Clin. Pharmacol. Ther. 35 (10) (1997) 401–413.
[13] H. Derendorf, B. Meibohm, Modeling of pharmacokinetic/pharmacodynamic (PK/
PD) relationships: concepts and perspectives, Pharm. Res. 16 (2) (1999) 176–185.
[14] L. Rossi, et al., Engineering erythrocytes for the modulation of drugs’ and con-
trasting agents’ pharmacokinetics and biodistribution, Adv. Drug Deliv. Rev. 106
(Pt A) (2016) 73–87.
[15] H.H. Wong, S. Halford, Dose-limiting toxicity and maximum tolerated dose: still fit
for purpose? Lancet Oncol. 16 (13) (2015) 1287–1288.
[16] H.G. Stampfer, G.M. Gabb, S.B. Dimmitt, Why Maximum Tolerated Dose? (2019).
[17] C. Keywood, Chapter 17 - Clinical development: present and future, in: R.G. Hill,
H.P. Rang (Eds.), Drug Discovery and Development, Second edition, Churchill
Livingstone, 2013, pp. 239–258.
[18] K. Venkatakrishnan, et al., Optimizing oncology therapeutics through quantitative
translational and clinical pharmacology: challenges and opportunities, Clin.
Pharmacol. Ther. 97 (1) (2015) 37–54.
[19] J. Zugazagoitia, et al., Current challenges in cancer treatment, Clin. Ther. 38 (7)
(2016) 1551–1566.
[20] M. Pein, T. Oskarsson, Microenvironment in metastasis: roadblocks and supportive
niches, Am. J. Physiol. Cell. Physiol. 309 (10) (2015) C627–C638.
[21] J. Brabek, D. Rosel, M. Fernandes, Pragmatic medicine in solid cancer: a transla-
tional alternative to precision medicine, OncoTargets Ther. 9 (2016) 1839–1855.
[22] S. Maman, I.P. Witz, A history of exploring cancer in context, Nat. Rev. Cancer 18
(6) (2018) 359–376.
[23] P. Vaupel, L. Harrison, Tumor hypoxia: causative factors, compensatory me-
chanisms, and cellular response, Oncologist 9 (Suppl. 5) (2004) 4–9.
[24] P.M. Gullino, S.H. Clark, F.H. Grantham, The interstitial fluid of solid tumors,
Cancer Res. 24 (1964) 780–794.
[25] Y. Kato, et al., Acidic extracellular microenvironment and cancer, Cancer Cell Int.
13 (1) (2013) 89.
[26] H. Maeda, H. Nakamura, J. Fang, The EPR effect for macromolecular drug delivery
to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and
distinct tumor imaging in vivo, Adv. Drug Deliv. Rev. 65 (1) (2013) 71–79.
[27] B. Warren, Tumor blood circulation: angiogenesis, vascular morphology and blood
flow of experimental and human tumors, The Vascular Morphology of Tumors,
CRC Press, Inc., Florida, 1979, pp. 1–47.
[28] D.J. Chaplin, P.L. Olive, R.E. Durand, Intermittent blood flow in a murine tumor:
radiobiological effects, Cancer Res. 47 (2) (1987) 597–601.
[29] T.P. Padera, E.F.J. Meijer, L.L. Munn, The lymphatic system in disease processes
and cancer progression, Annu. Rev. Biomed. Eng. 18 (2016) 125–158.
[30] C.C. DuFort, M.J. Paszek, V.M. Weaver, Balancing forces: architectural control of
mechanotransduction, Nat. Rev. Mol. Cell. Biol. 12 (5) (2011) 308–319.
[31] R. Xu, A. Boudreau, M.J. Bissell, Tissue architecture and function: dynamic re-
ciprocity via extra- and intra-cellular matrices, Cancer Metastasis Rev. 28 (1–2)
(2009) 167–176.
[32] C.H. Heldin, K. Rubin, K. Pietras, A. Ostman, High interstitial fluid pressure - an
obstacle in cancer therapy, Nat. Rev. Cancer 4 (10) (2004) 806–813.
[33] M.A. Swartz, A.W. Lund, Lymphatic and interstitial flow in the tumour micro-
environment: linking mechanobiology with immunity, Nat. Rev. Cancer 12 (2012)
210.
[34] Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and
the antitumor agent smancs, Cancer Res. 46 (12 Pt 1) (1986) 6387–6392.
[35] H. Maeda, Tumor-selective delivery of macromolecular drugs via the EPR effect:
background and future prospects, Bioconjug. Chem. 21 (5) (2010) 797–802.
[36] F. Danhier, To exploit the tumor microenvironment: since the EPR effect fails in
the clinic, what is the future of nanomedicine? J. Control. Release 244 (2016)
108–121.
[37] M. Yu, J. Zheng, Clearance pathways and tumor targeting of imaging nano-
particles, ACS Nano 9 (7) (2015) 6655–6674.
[38] S.K. Hobbs, et al., Regulation of transport pathways in tumor vessels: role of tumor
type and microenvironment, Proc. Natl. Acad. Sci. U. S. A. 95 (8) (1998)
4607–4612.
[39] J.S. Suk, Q. Xu, N. Kim, J. Hanes, L.M. Ensign, PEGylation as a strategy for im-
proving nanoparticle-based drug and gene delivery, Adv. Drug Deliv. Rev. 99 (Pt
A) (2016) 28–51.
[40] Q. Yang, S.K. Lai, Anti-PEG immunity: emergence, characteristics, and un-
addressed questions, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7 (5)
(2015) 655–677.
[41] Y. Bi, et al., Actively targeted nanoparticles for drug delivery to tumor, Curr. Drug
Metab. 17 (8) (2016) 763–782.
[42] J.W. Nichols, Y.H. Bae, EPR: evidence and fallacy, J. Control. Release 190 (2014)
451–464.
[43] K. Park, The beginning of the end of the nanomedicine hype, J. Control. Release
305 (2019) 221–222.
[44] K.F. Pirollo, E.H. Chang, Does a targeting ligand influence nanoparticle tumor
localization or uptake? Trends Biotechnol. 26 (10) (2008) 552–558.
[45] S. Wilhelm, et al., Analysis of nanoparticle delivery to tumours, Nat. Rev. Mater. 1
(2016) 16014.
[46] G. Baronzio, G. Parmar, M. Baronzio, Overview of methods for overcoming hin-
drance to drug delivery to tumors, with special attention to tumor interstitial fluid,
Front. Oncol. 5 (2015) 165.
[47] W. Jiang, Y. Huang, Y. An, B.Y. Kim, Remodeling tumor vasculature to enhance
delivery of intermediate-sized nanoparticles, ACS Nano 9 (9) (2015) 8689–8696.
[48] R.K. Jain, Normalization of tumor vasculature: an emerging concept in anti-
angiogenic therapy, Science (New York, N.Y.) 307 (5706) (2005) 58–62.
[49] J.S. Park, et al., Normalization of tumor vessels by Tie2 activation and Ang2 in-
hibition enhances drug delivery and produces a favorable tumor microenviron-
ment, Cancer Cell 30 (6) (2016) 953–967.
[50] A.R. Cantelmo, et al., Inhibition of the glycolytic activator PFKFB3 in endothelium
induces tumor vessel normalization, impairs metastasis, and improves che-
motherapy, Cancer Cell 30 (6) (2016) 968–985.
[51] S. Sindhwani, et al., The entry of nanoparticles into solid tumours, Nat. Mater. 19
(5) (2020) 566–575.
[52] S. Pandit, D. Dutta, S. Nie, Active transcytosis and new opportunities for cancer
nanomedicine, Nat. Mater. 19 (5) (2020) 478–480.
[53] Y. Yuan, Spatial heterogeneity in the tumor microenvironment, Cold Spring Harb.
Perspect. Med. 6 (8) (2016) a026583.
[54] C. Murdoch, A. Giannoudis, C.E. Lewis, Mechanisms regulating the recruitment of
macrophages into hypoxic areas of tumors and other ischemic tissues, Blood 104
(8) (2004) 2224–2234.
[55] J. Goc, W.H. Fridman, C. Sautes-Fridman, M.C. Dieu-Nosjean, Characteristics of
tertiary lymphoid structures in primary cancers, Oncoimmunology 2 (12) (2013)
e26836.
[56] L.L. van der Woude, M.A.J. Gorris, A. Halilovic, C.G. Figdor, I.J.M. de Vries,
Migrating into the tumor: a roadmap for T cells, Trends Cancer 3 (11) (2017)
797–808.
[57] J.N. Kather, et al., Topography of cancer-associated immune cells in human solid
tumors, eLife 7 (2018) e36967.
[58] D. Vestweber, How leukocytes cross the vascular endothelium, Nat. Rev. Immunol.
15 (11) (2015) 692–704.
[59] M. Yang, D. McKay, J.W. Pollard, C.E. Lewis, Diverse functions of macrophages in
F. Combes, et al. Journal of Controlled Release 327 (2020) 70–87
82
different tumor microenvironments, Cancer Res. 78 (19) (2018) 5492.
[60] H.F. Dvorak, Tumors: wounds that do not heal. Similarities between tumor stroma
generation and wound healing, N. Engl. J. Med. 315 (26) (1986) 1650–1659.
[61] E. Elinav, et al., Inflammation-induced cancer: crosstalk between tumours, im-
mune cells and microorganisms, Nat. Rev. Cancer 13 (11) (2013) 759–771.
[62] R. Sackstein, T. Schatton, S.R. Barthel, T-lymphocyte homing: an under-
appreciated yet critical hurdle for successful cancer immunotherapy, Lab. Investig.
97 (2017) 669.
[63] A.D. Luster, R. Alon, U.H. von Andrian, Immune cell migration in inflammation:
present and future therapeutic targets, Nat. Immunol. 6 (12) (2005) 1182–1190.
[64] W.A. Muller, Transendothelial migration: unifying principles from the endothelial
perspective, Immunol. Rev. 273 (1) (2016) 61–75.
[65] T.R. Lee, et al., On the near-wall accumulation of injectable particles in the mi-
crocirculation: smaller is not better, Sci. Rep. 3 (2013) 2079.
[66] M.P. Bevilacqua, R.M. Nelson, Selectins, J. Clin. Invest. 91 (2) (1993) 379–387.
[67] S. Weinbaum, J.M. Tarbell, E.R. Damiano, The structure and function of the en-
dothelial glycocalyx layer, Annu. Rev. Biomed. Eng. 9 (2007) 121–167.
[68] T. Yago, et al., Catch bonds govern adhesion through L-selectin at threshold shear,
J. Cell Biol. 166 (6) (2004) 913–923.
[69] J. Kappelmayer, B. Nagy Jr., The interaction of selectins and PSGL-1 as a key
component in thrombus formation and cancer progression, Biomed. Res. Int. 2017
(2017) 6138145.
[70] R.P. McEver, C. Zhu, Rolling cell adhesion, Annu. Rev. Cell Dev. Biol. 26 (2010)
363–396.
[71] E. Crockett-Torabi, Selectins and mechanisms of signal transduction, J. Leukoc.
Biol. 63 (1) (1998) 1–14.
[72] R.P. McEver, Selectins: initiators of leucocyte adhesion and signalling at the vas-
cular wall, Cardiovasc. Res. 107 (3) (2015) 331–339.
[73] S.C. Fagerholm, C. Guenther, M. Llort Asens, T. Savinko, L.M. Uotila, Beta2-in-
tegrins and interacting proteins in leukocyte trafficking, immune suppression, and
immunodeficiency disease, Front. Immunol. 10 (2019) 254.
[74] I.D. Campbell, M.J. Humphries, Integrin structure, activation, and interactions,
Cold Spring Harb. Perspect. Biol. 3 (3) (2011).
[75] H. Harjunpää, M. Llort Asens, C. Guenther, S.C. Fagerholm, Cell adhesion mole-
cules and their roles and regulation in the immune and tumor microenvironment,
Front. Immunol. 10 (2019) 1078.
[76] J. Li, et al., Conformational Equilibria and Intrinsic Affinities Define Integrin
Activation, 36(5) (2017), pp. 629–645.
[77] M. Shimaoka, J. Takagi, T.A. Springer, Conformational regulation of integrin
structure and function, Annu. Rev. Biophys. Biomol. Struct. 31 (2002) 485–516.
[78] C. Berlin, et al., α4 integrins mediate lymphocyte attachment and rolling under
physiologic flow, Cell 80 (3) (1995) 413–422.
[79] T. Yago, N. Zhang, L. Zhao, C.S. Abrams, R.P. McEver, Selectins and Chemokines
Use Shared and Distinct Signals to Activate beta2 Integrins in Neutrophils, 2(7)
(2018), pp. 731–744.
[80] M. Phillipson, et al., Intraluminal crawling of neutrophils to emigration sites: a
molecularly distinct process from adhesion in the recruitment cascade, J. Exp.
Med. 203 (12) (2006) 2569–2575.
[81] R. Sumagin, H. Prizant, E. Lomakina, R.E. Waugh, I.H. Sarelius, LFA-1 and Mac-1
define characteristically different intralumenal crawling and emigration patterns
for monocytes and neutrophils in situ, J. Immunol. (Baltimore, Md. : 1950) 185
(11) (2010) 7057–7066.
[82] W.A. Muller, How endothelial cells regulate transmigration of leukocytes in the
inflammatory response, Am. J. Pathol. 184 (4) (2014) 886–896.
[83] S.K. Shaw, et al., Coordinated redistribution of leukocyte LFA-1 and endothelial
cell ICAM-1 accompany neutrophil transmigration, J. Exp. Med. 200 (12) (2004)
1571–1580.
[84] O. Barreiro, et al., Dynamic interaction of VCAM-1 and ICAM-1 with moesin and
ezrin in a novel endothelial docking structure for adherent leukocytes, J. Cell Biol.
157 (7) (2002) 1233–1245.
[85] S. Wang, et al., Venular basement membranes contain specific matrix protein low
expression regions that act as exit points for emigrating neutrophils, J. Exp. Med.
203 (6) (2006) 1519–1532.
[86] M.B. Voisin, A. Woodfin, S. Nourshargh, Monocytes and neutrophils exhibit both
distinct and common mechanisms in penetrating the vascular basement membrane
in vivo, Arterioscler. Thromb. Vasc. Biol. 29 (8) (2009) 1193–1199.
[87] R. Hallmann, et al., The regulation of immune cell trafficking by the extracellular
matrix, Curr. Opin. Cell Biol. 36 (2015) 54–61.
[88] K. Ley, C. Laudanna, M.I. Cybulsky, S. Nourshargh, Getting to the site of in-
flammation: the leukocyte adhesion cascade updated, Nat. Rev. Immunol. 7 (9)
(2007) 678–689.
[89] L.C. Kelley, L.L. Lohmer, E.J. Hagedorn, D.R. Sherwood, Traversing the basement
membrane in vivo: a diversity of strategies, J. Cell Biol. 204 (3) (2014) 291.
[90] R.O. Hynes, The extracellular matrix: not just pretty fibrils, Science (New York,
N.Y.) 326 (5957) (2009) 1216–1219.
[91] I. Stamenkovic, Extracellular matrix remodelling: the role of matrix metallopro-
teinases, J. Pathol. 200 (4) (2003) 448–464.
[92] G.G. Vaday, et al., Combinatorial signals by inflammatory cytokines and chemo-
kines mediate leukocyte interactions with extracellular matrix, J. Leukoc. Biol. 69
(6) (2001) 885–892.
[93] T. Vorup-Jensen, et al., Exposure of acidic residues as a danger signal for re-
cognition of fibrinogen and other macromolecules by integrin alphaXbeta2, Proc.
Natl. Acad. Sci. U. S. A. 102 (5) (2005) 1614–1619.
[94] K. Wolf, R. Muller, S. Borgmann, E.B. Brocker, P. Friedl, Amoeboid shape change
and contact guidance: T-lymphocyte crawling through fibrillar collagen is in-
dependent of matrix remodeling by MMPs and other proteases, Blood 102 (9)
(2003) 3262–3269.
[95] K. Wolf, et al., Physical limits of cell migration: control by ECM space and nuclear
deformation and tuning by proteolysis and traction force, J. Cell Biol. 201 (7)
(2013) 1069–1084.
[96] B.A. David, P. Kubes, Exploring the complex role of chemokines and chemoat-
tractants in vivo on leukocyte dynamics, Immunol. Rev. 289 (1) (2019) 9–30.
[97] D.F. Legler, M. Thelen, Chemokines: chemistry, biochemistry and biological
function, Chimia 70 (12) (2016) 856–859.
[98] A.E. Proudfoot, et al., Glycosaminoglycan binding and oligomerization are es-
sential for the in vivo activity of certain chemokines, Proc. Natl. Acad. Sci. U. S. A.
100 (4) (2003) 1885–1890.
[99] B. Heit, S. Tavener, E. Raharjo, P. Kubes, An intracellular signaling hierarchy
determines direction of migration in opposing chemotactic gradients, J. Cell Biol.
159 (1) (2002) 91–102.
[100] H. Lortat-Jacob, A. Grosdidier, A. Imberty, Structural diversity of heparan sulfate
binding domains in chemokines, Proc. Natl. Acad. Sci. 99 (3) (2002) 1229.
[101] M. Binnewies, et al., Understanding the tumor immune microenvironment (TIME)
for effective therapy, Nat. Med. 24 (5) (2018) 541–550.
[102] G. Bindea, et al., Spatiotemporal dynamics of intratumoral immune cells reveal the
immune landscape in human cancer, Immunity 39 (4) (2013) 782–795.
[103] S. Hendry, et al., Assessing tumor-infiltrating lymphocytes in solid tumors: a
practical review for pathologists and proposal for a standardized method from the
International Immunooncology Biomarkers Working Group: part 1: assessing the
host immune response, TILs in invasive breast carcinoma and ductal carcinoma in
situ, metastatic tumor deposits and areas for further research, Adv. Anat. Pathol.
24 (5) (2017) 235–251.
[104] S. Spranger, Mechanisms of tumor escape in the context of the T-cell-inflamed and
the non-T-cell-inflamed tumor microenvironment, Int. Immunol. 28 (8) (2016)
383–391.
[105] J.C. Roth, D.T. Curiel, L. Pereboeva, Cell vehicle targeting strategies, Gene Ther.
15 (2008) 716.
[106] O.S. Blomberg, L. Spagnuolo, K.E. de Visser, Immune regulation of metastasis:
mechanistic insights and therapeutic opportunities, Dis. Model Mech. 11 (10)
(2018) (dmm036236).
[107] W.A. Lim, C.H. June, The principles of engineering immune cells to treat cancer,
Cell 168 (4) (2017) 724–740.
[108] M.A. Fischbach, J.A. Bluestone, W.A. Lim, Cell-based therapeutics: the next pillar
of medicine, Sci. Transl. Med. 5 (179) (2013) (179ps177).
[109] W.A. Lim, Designing customized cell signalling circuits, Nat. Rev. Mol. Cell. Biol.
11 (6) (2010) 393–403.
[110] K. Harrington, et al., Cells as vehicles for cancer gene therapy: the missing link
between targeted vectors and systemic delivery? Hum. Gene Ther. 13 (11) (2002)
1263–1280.
[111] M. Hamidi, A. Zarrin, M. Foroozesh, S. Mohammadi-Samani, Applications of
carrier erythrocytes in delivery of biopharmaceuticals, J. Control. Release 118 (2)
(2007) 145–160.
[112] K. Kinosita, T.Y. Tsong, Survival of sucrose-loaded erythrocytes in the circulation,
Nature 272 (5650) (1978) 258–260.
[113] C.H. Villa, et al., Delivery of drugs bound to erythrocytes: new avenues for an old
intravascular carrier, Ther. Deliv. 6 (7) (2015) 795–826.
[114] F. Pierigè, N. Bigini, L. Rossi, M. Magnani, Reengineering red blood cells for cel-
lular therapeutics and diagnostics, Wiley Interdiscip. Rev. 9 (5) (2017) e1454.
[115] E. Lee, et al., The RNA in reticulocytes is not just debris: it is necessary for the final
stages of erythrocyte formation, Blood Cells Mol. Dis. 53 (1–2) (2014) 1–10.
[116] F.J. Alvarez, et al., Cross-linking treatment of loaded erythrocytes increases de-
livery of encapsulated substance to macrophages, Biotechnol. Appl. Biochem. 27
(2) (1998) 139–143.
[117] F.J. Alvarez, J.A. Jordan, A. Herraez, J.C. Diez, M.C. Tejedor, Hypotonically
loaded rat erythrocytes deliver encapsulated substances into peritoneal macro-
phages, J. Biochem. 123 (2) (1998) 233–239.
[118] S.G. Moreno, Depleting macrophages in vivo with clodronate-liposomes, Methods
Mol. Biol. (Clifton, N.J.) 1784 (2018) 259–262.
[119] P. Burger, P. Hilarius-Stokman, D. de Korte, T.K. van den Berg, R. van Bruggen,
CD47 functions as a molecular switch for erythrocyte phagocytosis, Blood 119
(23) (2012) 5512–5521.
[120] E. Bashar, K. Gregory-Evans, Magnetic Nanoparticles in Cell-based Therapies,
(2016), pp. 161–184.
[121] R.J. Price, D.M. Skyba, S. Kaul, T.C. Skalak, Delivery of colloidal particles and red
blood cells to tissue through microvessel ruptures created by targeted microbubble
destruction with ultrasound, Circulation 98 (13) (1998) 1264–1267.
[122] V.N. Smirnov, et al., Carrier-directed targeting of liposomes and erythrocytes to
denuded areas of vessel wall, Proc. Natl. Acad. Sci. U. S. A. 83 (17) (1986)
6603–6607.
[123] H. Vink, B.R. Duling, Identification of distinct luminal domains for macro-
molecules, erythrocytes, and leukocytes within mammalian capillaries, Circ. Res.
79 (3) (1996) 581–589.
[124] A. Lucas, D. Lam, P. Cabrales, Doxorubicin-loaded red blood cells reduced cardiac
toxicity and preserved anticancer activity, Drug Deliv. 26 (1) (2019) 433–442.
[125] N.M. La-Beck, A.A. Gabizon, Nanoparticle interactions with the immune system:
clinical implications for liposome-based cancer chemotherapy, Front. Immunol. 8
(2017) 416.
[126] Y. Lu, Q. Hu, C. Jiang, Z. Gu, Platelet for drug delivery, Curr. Opin. Biotechnol. 58
(2019) 81–91.
[127] J.E. Italiano Jr.et al., Angiogenesis is regulated by a novel mechanism: pro- and
antiangiogenic proteins are organized into separate platelet alpha granules and
differentially released, Blood 111 (3) (2008) 1227–1233.
F. Combes, et al. Journal of Controlled Release 327 (2020) 70–87
83
[128] N. Ortiz-Otero, Z. Mohamed, M.R. King, Platelet-based drug delivery for cancer
applications, Adv. Exp. Med. Biol. 1092 (2018) 235–251.
[129] T. Burnouf, H.A. Goubran, M.L. Chou, D. Devos, M. Radosevic, Platelet micro-
particles: detection and assessment of their paradoxical functional roles in disease
and regenerative medicine, Blood Rev. 28 (4) (2014) 155–166.
[130] D. Buergy, F. Wenz, C. Groden, M.A. Brockmann, Tumor–platelet interaction in
solid tumors, Int. J. Cancer 130 (12) (2012) 2747–2760.
[131] B. Ho-Tin-Noe, T. Goerge, S.M. Cifuni, D. Duerschmied, D.D. Wagner, Platelet
granule secretion continuously prevents intratumor hemorrhage, Cancer Res. 68
(16) (2008) 6851–6858.
[132] P. Xu, et al., Doxorubicin-loaded platelets as a smart drug delivery system: an
improved therapy for lymphoma, Sci. Rep. 7 (2017) 42632.
[133] P. Xu, et al., Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a
novel targeted delivery system for lymphoma treatment with cardiopulmonary
avoidance, Oncotarget 8 (35) (2017) 58322–58337.
[134] Y. Zhang, G. Liu, J. Wei, G. Nie, Platelet membrane-based and tumor-associated
platelettargeted drug delivery systems for cancer therapy, Front. Med. 12 (6)
(2018) 667–677.
[135] C. Wang, et al., In situ activation of platelets with checkpoint inhibitors for post-
surgical cancer immunotherapy, Nat. Biomed. Eng. 1 (2017) 0011.
[136] X. Han, et al., Platelets as platforms for inhibition of tumor recurrence post-phy-
sical therapy by delivery of anti-PD-L1 checkpoint antibody, J. Control. Release
304 (2019) 233–241.
[137] J.L. Sieow, S.Y. Gun, S.C. Wong, The sweet surrender: how myeloid cell metabolic
plasticity shapes the tumor microenvironment, Front. Cell Dev. Biol. 6 (168)
(2018).
[138] R.M. Awad, Y. De Vlaeminck, J. Maebe, C. Goyvaerts, K. Breckpot, Turn back the
TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression,
Front. Immunol. 9 (2018) 1977.
[139] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (5)
(2011) 646–674.
[140] M. Karin, F.R. Greten, NF-kappaB: linking inflammation and immunity to cancer
development and progression, Nat. Rev. Immunol. 5 (10) (2005) 749–759.
[141] F. Veglia, M. Perego, Myeloid-derived Suppressor Cells Coming of Age, 19(2)
(2018), pp. 108–119.
[142] M. Kiss, S. Van Gassen, K. Movahedi, Y. Saeys, D. Laoui, Myeloid cell hetero-
geneity in cancer: not a single cell alike, Cell. Immunol. 330 (2018) 188–201.
[143] H. Peinado, S. Lavotshkin, D. Lyden, The secreted factors responsible for pre-
metastatic niche formation: old sayings and new thoughts, Semin. Cancer Biol. 21
(2) (2011) 139–146.
[144] J. Jablonska, S. Lang, R.V. Sionov, Z. Granot, The regulation of pre-metastatic
niche formation by neutrophils, Oncotarget 8 (67) (2017) 112132–112144.
[145] T. Loos, A. Mortier, P. Proost, Chapter 1. Isolation, identification, and production
of posttranslationally modified chemokines, Methods Enzymol. 461 (2009) 3–29.
[146] A. Mortier, J. Van Damme, P. Proost, Regulation of chemokine activity by post-
translational modification, Pharmacol. Ther. 120 (2) (2008) 197–217.
[147] B. Molon, et al., Chemokine nitration prevents intratumoral infiltration of antigen-
specific T cells, J. Exp. Med. 208 (10) (2011) 1949–1962.
[148] D. Chu, X. Dong, X. Shi, C. Zhang, Z. Wang, Neutrophil-based drug delivery sys-
tems, Adv. Mater. 30 (22) (2018) e1706245.
[149] C. Summers, et al., Neutrophil kinetics in health and disease, Trends Immunol. 31
(8) (2010) 318–324.
[150] J.M. Petty, C.C. Lenox, D.J. Weiss, M.E. Poynter, B.T. Suratt, Crosstalk between
CXCR4/stromal derived factor-1 and VLA-4/VCAM-1 pathways regulates neu-
trophil retention in the bone marrow, J. Immunol. (Baltimore, Md. : 1950) 182 (1)
(2009) 604–612.
[151] A.E. Ekpenyong, N. Toepfner, E.R. Chilvers, J. Guck, Mechanotransduction in
neutrophil activation and deactivation, Biochim. Biophys. Acta 11 (Part B) (2015)
3105–3116.
[152] A.M. Mauer, J.W. Athens, H. Ashenbrucker, G.E. Cartwright, M.M. Wintrobe,
Leukokinetic studies. II. A method for labeling granulocytes in vitro with radio-
active diisopropylfluorophosphate (DFP), J. Clin. Invest. 39 (9) (1960)
1481–1486.
[153] J.W. Athens, et al., Leukokinetic studies. III. The distribution of granulocytes in the
blood of normal subjects, J. Clin. Investig. 40 (1961) 159–164.
[154] J.W. Athens, et al., Leukokinetic studies. IV. The total blood, circulating and
marginal granulocyte pools and the granulocyte turnover rate in normal subjects,
J. Clin. Invest. 40 (1961) 989–995.
[155] W. MacNee, C. Selby, New perspectives on basic mechanisms in lung disease. 2.
Neutrophil traffic in the lungs: role of haemodynamics, cell adhesion, and de-
formability, Thorax 48 (1) (1993) 79–88.
[156] C. Summers, et al., Neutrophil kinetics in health and disease, Trends Immunol. 31
(8) (2010) 318–324.
[157] W.M. Kuebler, A.E. Goetz, The marginated pool, Eur. Surg. Res. 34 (1–2) (2002)
92–100.
[158] B.A. Martin, J.L. Wright, H. Thommasen, J.C. Hogg, Effect of pulmonary blood
flow on the exchange between the circulating and marginating pool of poly-
morphonuclear leukocytes in dog lungs, J. Clin. Invest. 69 (6) (1982) 1277–1285.
[159] C.M. Doerschuk, N. Beyers, H.O. Coxson, B. Wiggs, J.C. Hogg, Comparison of
neutrophil and capillary diameters and their relation to neutrophil sequestration
in the lung, J. Appl. Physiol. (Bethesda, Md. : 1985) 74 (6) (1993) 3040–3045.
[160] B.T. Suratt, et al., Neutrophil maturation and activation determine anatomic site of
clearance from circulation, Am. J. Physiol. 281 (4) (2001) L913–L921.
[161] J. Shi, G.E. Gilbert, Y. Kokubo, T. Ohashi, Role of the liver in regulating numbers
of circulating neutrophils, Blood 98 (4) (2001) 1226–1230.
[162] J. Grommes, O. Soehnlein, Contribution of neutrophils to acute lung injury, Mol.
Med. 17 (3–4) (2011) 293–307.
[163] J.M. Petty, et al., Pulmonary stromal-derived factor-1 expression and effect on
neutrophil recruitment during acute lung injury, J. Immunol. (Baltimore, Md. :
1950) 178 (12) (2007) 8148–8157.
[164] I. Miralda, S.M. Uriarte, K.R. McLeish, Multiple phenotypic changes define neu-
trophil priming, Front. Cell. Infect. Microbiol. 7 (2017) 217.
[165] R.S. Frank, Time-dependent alterations in the deformability of human neutrophils
in response to chemotactic activation, Blood 76 (12) (1990) 2606.
[166] C. Summers, et al., Pulmonary retention of primed neutrophils: a novel protective
host response, which is impaired in the acute respiratory distress syndrome,
Thorax 69 (7) (2014) 623–629.
[167] S. de Oliveira, et al., Cxcl8 (IL-8) mediates neutrophil recruitment and behavior in
the zebrafish inflammatory response, J. Immunol. (Baltimore, Md. : 1950) 190 (8)
(2013) 4349–4359.
[168] A.M. Condliffe, E.R. Chilvers, C. Haslett, I. Dransfield, Priming differentially reg-
ulates neutrophil adhesion molecule expression/function, Immunology 89 (1)
(1996) 105–111.
[169] K.L. Vogt, C. Summers, E.R. Chilvers, Priming and De-priming of Neutrophil
Responses In Vitro and In Vivo, 48 (2) (2018), p. e12967.
[170] J.M. Paulsson, S.H. Jacobson, J. Lundahl, Neutrophil activation during transmi-
gration in vivo and in vitro A translational study using the skin chamber model, J.
Immunol. Methods 361 (1–2) (2010) 82–88.
[171] T.N. Mayadas, X. Cullere, C.A. Lowell, The multifaceted functions of neutrophils,
Annu. Rev. Pathol. 9 (2014) 181–218.
[172] C. Eyileten, et al., Immune cells in cancer therapy and drug delivery, Mediat.
Inflamm. 2016 (2016) 5230219.
[173] E.B. Eruslanov, S. Singhal, S.M. Albelda, Mouse versus human neutrophils in
cancer: a major knowledge gap, Trends Cancer 3 (2) (2017) 149–160.
[174] G.B. Segel, M.W. Halterman, M.A. Lichtman, The paradox of the neutrophil’s role
in tissue injury, J. Leukoc. Biol. 89 (3) (2011) 359–372.
[175] S.O. Wendel, et al., Cell based drug delivery: micrococcus luteus loaded neu-
trophils as chlorhexidine delivery vehicles in a mouse model of liver abscesses in
cattle, PLoS One 10 (5) (2015) e0128144.
[176] D. Chu, X. Dong, X. Shi, C. Zhang, Z. Wang, Neutrophil. Based Drug Deliv. Syst. 30
(22) (2018) e1706245.
[177] D. Chu, X. Dong, Q. Zhao, J. Gu, Z. Wang, Photosensitization priming of tumor
microenvironments improves delivery of nanotherapeutics via neutrophil in-
filtration, Adv. Mater. 29 (27) (2017) 1701021.
[178] J. Xue, et al., Neutrophil-mediated anticancer drug delivery for suppression of
postoperative malignant glioma recurrence, Nat. Nanotechnol. 12 (7) (2017)
692–700.
[179] G.A. Ramirez, et al., Eosinophils from physiology to disease: a comprehensive
review, Biomed. Res. Int. 2018 (2018) 9095275.
[180] K.D. Stone, C. Prussin, D.D. Metcalfe, IgE, mast cells, basophils, and eosinophils, J.
Allergy Clin. Immunol. 125 (2 Suppl 2) (2010) S73–S80.
[181] J.J. Lee, E.A. Jacobsen, M.P. McGarry, R.P. Schleimer, N.A. Lee, Eosinophils in
health and disease: the LIAR hypothesis, Clin. Exp. Allergy 40 (4) (2010) 563–575.
[182] S.A. Cormier, et al., Pivotal advance: eosinophil infiltration of solid tumors is an
early and persistent inflammatory host response, J. Leukoc. Biol. 79 (6) (2006)
1131–1139.
[183] T. Wen, J.A. Besse, M.K. Mingler, P.C. Fulkerson, M.E. Rothenberg, Eosinophil
adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in
vivo, Proc. Natl. Acad. Sci. U. S. A. 110 (15) (2013) 6067–6072.
[184] A.K. Johansson, S. Sergejeva, M. Sjostrand, J.J. Lee, J. Lotvall, Allergen-induced
traffic of bone marrow eosinophils, neutrophils and lymphocytes to airways, Eur.
J. Immunol. 34 (11) (2004) 3135–3145.
[185] N. Charles, J.M. Chemouny, E. Daugas, Basophil involvement in lupus nephritis: a
basis for innovation in daily care, Nephrol. Dial. Transplant. 34 (5) (2018)
750–756.
[186] B. Min, M.A. Brown, G. Legros, Understanding the roles of basophils: breaking
dawn, Immunology 135 (3) (2012) 192–197.
[187] H. Karasuyama, K. Mukai, K. Obata, Y. Tsujimura, T. Wada, Nonredundant roles of
basophils in immunity, Annu. Rev. Immunol. 29 (2011) 45–69.
[188] M.C. Siracusa, et al., TSLP promotes interleukin-3-independent basophil haema-
topoiesis and type 2 inflammation, Nature 477 (7363) (2011) 229–233.
[189] M. Iikura, et al., Chemokine receptors in human basophils: inducible expression of
functional CXCR4, J. Leukoc. Biol. 70 (1) (2001) 113–120.
[190] S. Yona, et al., Fate mapping reveals origins and dynamics of monocytes and tissue
macrophages under homeostasis, Immunity 38 (1) (2013) 79–91.
[191] D. Hashimoto, et al., Tissue-resident macrophages self-maintain locally
throughout adult life with minimal contribution from circulating monocytes,
Immunity 38 (4) (2013) 792–804.
[192] K. Liu, et al., In vivo analysis of dendritic cell development and homeostasis,
Science (New York, N.Y.) 324 (5925) (2009) 392.
[193] C. Auffray, et al., Monitoring of blood vessels and tissues by a population of
monocytes with patrolling behavior, Science (New York, N.Y.) 317 (5838) (2007)
666–670.
[194] F. Ginhoux, S. Jung, Monocytes and macrophages: developmental pathways and
tissue homeostasis, Nat. Rev. Immunol. 14 (2014) 392.
[195] N.V. Serbina, E.G. Pamer, Monocyte emigration from bone marrow during bac-
terial infection requires signals mediated by chemokine receptor CCR2, Nat.
Immunol. 7 (3) (2006) 311–317.
[196] C.S. Robbins, et al., Extramedullary hematopoiesis generates Ly-6C(high) mono-
cytes that infiltrate atherosclerotic lesions, Circulation 125 (2) (2012) 364–374.
[197] F.K. Swirski, et al., Identification of splenic reservoir monocytes and their de-
ployment to inflammatory sites, Science (New York, N.Y.) 325 (5940) (2009)
F. Combes, et al. Journal of Controlled Release 327 (2020) 70–87
84
612–616.
[198] K.P. O’Dea, et al., Mobilization and margination of bone marrow Gr-1high
monocytes during subclinical endotoxemia predisposes the lungs toward acute
injury, J. Immunol. (Baltimore, Md. : 1950) 182 (2) (2009) 1155–1166.
[199] K.E. O’Connell, et al., Practical murine hematopathology: a comparative review
and implications for research, Comp. Med. 65 (2) (2015) 96–113.
[200] P.Y. Lee, J.X. Wang, E. Parisini, C.C. Dascher, P.A. Nigrovic, Ly6 family proteins in
neutrophil biology, J. Leukoc. Biol. 94 (4) (2013) 585–594.
[201] F. Geissmann, S. Jung, D.R. Littman, Blood monocytes consist of two principal
subsets with distinct migratory properties, Immunity 19 (1) (2003) 71–82.
[202] A. Mildner, et al., Genomic characterization of murine monocytes reveals C/
EBPbeta transcription factor dependence of Ly6C(-) cells, Immunity 46 (5) (2017)
849–862 (e847).
[203] C. Varol, et al., Monocytes give rise to mucosal, but not splenic, conventional
dendritic cells, J. Exp. Med. 204 (1) (2007) 171–180.
[204] A. Mildner, et al., CCR2+Ly-6Chi monocytes are crucial for the effector phase of
autoimmunity in the central nervous system, Brain J. Neurol. 132 (Pt 9) (2009)
2487–2500.
[205] P.J. Murray, Macrophage Polarization, Annu. Rev. Physiol. 79 (1) (2017)
541–566.
[206] L.C. Davies, S.J. Jenkins, J.E. Allen, P.R. Taylor, Tissue-resident macrophages, Nat.
Immunol. 14 (10) (2013) 986–995.
[207] S.J. Jenkins, et al., Local macrophage proliferation, rather than recruitment from
the blood, is a signature of TH2 inflammation, Science (New York, N.Y.) 332
(6035) (2011) 1284–1288.
[208] S.J. Jenkins, et al., IL-4 directly signals tissue-resident macrophages to proliferate
beyond homeostatic levels controlled by CSF-1, J. Exp. Med. 210 (11) (2013)
2477.
[209] C. Varol, et al., Intestinal lamina propria dendritic cell subsets have different
origin and functions, Immunity 31 (3) (2009) 502–512.
[210] C.S. Robbins, et al., Local proliferation dominates lesional macrophage accumu-
lation in atherosclerosis, Nat. Med. 19 (2013) 1166.
[211] T. Jia, et al., Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment
of inflammatory monocytes during< em> listeria monocytogenes< /em>
infection, J. Immunol. 180 (10) (2008) 6846.
[212] T. Gerhardt, K. Ley, Monocyte trafficking across the vessel wall, Cardiovasc. Res.
107 (3) (2015) 321–330.
[213] C.L. Maslin, K. Kedzierska, N.L. Webster, W.A. Muller, S.M. Crowe,
Transendothelial migration of monocytes: the underlying molecular mechanisms
and consequences of HIV-1 infection, Curr. HIV Res. 3 (4) (2005) 303–317.
[214] C. Shi, E.G. Pamer, Monocyte recruitment during infection and inflammation, Nat.
Rev. Immunol. 11 (11) (2011) 762–774.
[215] R.H. Wiltrout, et al., Distribution of peritoneal macrophage populations after in-
travenous injection in mice: differential effects of eliciting and activating agents, J.
Reticuloendothel. Soc. 34 (3) (1983) 253–269.
[216] R. Audran, B. Collet, A. Moisan, L. Toujas, Fate of mouse macrophages radi-
olabelled with PKH-95 and injected intravenously, Nucl. Med. Biol. 22 (6) (1995)
817–821.
[217] Y. Sawanobori, et al., Chemokine-mediated rapid turnover of myeloid-derived
suppressor cells in tumor-bearing mice, Blood 111 (12) (2008) 5457–5466.
[218] T. Lesimple, A. Moisan, L. Toujas, Autologous human macrophages and anti-tu-
mour cell therapy, Res. Immunol. 149 (7–8) (1998) 663–671.
[219] R. Andreesen, B. Hennemann, S.W. Krause, Adoptive immunotherapy of cancer
using monocyte-derived macrophages: rationale, current status, and perspectives,
J. Leukoc. Biol. 64 (4) (1998) 419–426.
[220] B.A. Teicher, Hypoxia and drug resistance, Cancer Metastasis Rev. 13 (2) (1994)
139–168.
[221] D. Lindsay, C.M. Garvey, S.M. Mumenthaler, J. Foo, Leveraging hypoxia-activated
prodrugs to prevent drug resistance in solid tumors, PLoS Comput. Biol. 12 (8)
(2016) e1005077.
[222] P.J. Bugelski, R. Kirsh, C. Buscarino, S.P. Corwin, G. Poste, Recruitment of exo-
genous macrophages into metastases at different stages of tumor growth, Cancer
Immunol. Immunother. 24 (2) (1987) 93–98.
[223] R. Parsa, et al., Adoptive transfer of immunomodulatory M2 macrophages pre-
vents type 1 diabetes in NOD mice, Diabetes 61 (11) (2012) 2881–2892.
[224] J.H. Seo, et al., Trafficking macrophage migration using reporter gene imaging
with human sodium iodide symporter in animal models of inflammation, J.
Nuclear Med. 51 (10) (2010) 1637–1643.
[225] L. Griffiths, et al., The macrophage - a novel system to deliver gene therapy to
pathological hypoxia, Gene Ther. 7 (3) (2000) 255–262.
[226] L. Carta, et al., Engineering of macrophages to produce IFN-gamma in response to
hypoxia, J. Immunol. (Baltimore, Md. : 1950) 166 (9) (2001) 5374–5380.
[227] R. Andreesen, B. Hennemann, S.W. Krause, Adoptive immunotherapy of cancer
using monocyte-derived macrophages: rationale, current status, and perspectives,
J. Leukoc. Biol. 64 (4) (1998) 419–426.
[228] M. Muthana, et al., Use of macrophages to target therapeutic adenovirus to human
prostate tumors, Cancer Res. 71 (5) (2011) 1805–1815.
[229] D.G. Roy, J.C. Bell, Cell carriers for oncolytic viruses: current challenges and fu-
ture directions, Oncolyt. Virother. 2 (2013) 47–56.
[230] M.A. Boemo, H.M. Byrne, Mathematical modelling of a hypoxia-regulated onco-
lytic virus delivered by tumour-associated macrophages, J. Theor. Biol. 461
(2019) 102–116.
[231] P.S. Jiang, et al., Irradiation enhances the ability of monocytes as nanoparticle
carrier for cancer therapy, PLoS One 10 (9) (2015) e0139043.
[232] T.D. McKee, et al., Degradation of fibrillar collagen in a human melanoma xeno-
graft improves the efficacy of an oncolytic herpes simplex virus vector, Cancer Res.
66 (5) (2006) 2509.
[233] G. Pawelec, C.P. Verschoor, S. Ostrand-Rosenberg, Myeloid-derived suppressor
cells: not only in tumor immunity, Front. Immunol. 10 (2019) 1099.
[234] D.I. Gabrilovich, et al., The terminology issue for myeloid-derived suppressor cells,
Cancer Res. 67 (1) (2007) 425–426.
[235] V. Bronte, et al., Recommendations for myeloid-derived suppressor cell nomen-
clature and characterization standards, Nat. Commun. 7 (2016) 12150.
[236] A.M. Bruger, et al., How to measure the immunosuppressive activity of, MDSC 68
(4) (2019) 631–644.
[237] L. Cassetta, et al., Deciphering myeloid-derived suppressor cells: isolation and
markers in humans, mice and non-human primates, Cancer Immunol.
Immunother. 68 (4) (2019) 687–697.
[238] V. Bronte, et al., Recommendations for myeloid-derived suppressor cell nomen-
clature and characterization standards, Nat. Commun. 7 (2016) 12150.
[239] D.I. Gabrilovich, S. Ostrand-Rosenberg, V. Bronte, Coordinated regulation of
myeloid cells by tumours, Nat. Rev. Immunol. 12 (4) (2012) 253–268.
[240] S. Brandau, et al., Myeloid-derived suppressor cells in the peripheral blood of
cancer patients contain a subset of immature neutrophils with impaired migratory
properties, J. Leukoc. Biol. 89 (2) (2011) 311–317.
[241] I.H. Younos, A.J. Dafferner, D. Gulen, H.C. Britton, J.E. Talmadge, Tumor reg-
ulation of myeloid-derived suppressor cell proliferation and trafficking, Int.
Immunopharmacol. 13 (3) (2012) 245–256.
[242] V. Cortez-Retamozo, et al., Origins of tumor-associated macrophages and neu-
trophils, Proc. Natl. Acad. Sci. U. S. A. 109 (7) (2012) 2491–2496.
[243] L. Levy, et al., Splenectomy inhibits non-small cell lung cancer growth by mod-
ulating anti-tumor adaptive and innate immune response, Oncoimmunology 4 (4)
(2015) e998469.
[244] B. Li, et al., CCL9/CCR1 induces myeloidderived suppressor cell recruitment to the
spleen in a murine H22 orthotopic hepatoma model, Oncol. Rep. 41 (1) (2019)
608–618.
[245] S.L. Highfill, et al., Disruption of CXCR2-mediated MDSC tumor trafficking en-
hances anti-PD1 efficacy, Sci. Transl. Med. 6 (237) (2014) (237ra267).
[246] L. Sun, et al., Inhibiting myeloid-derived suppressor cell trafficking enhances T cell
immunotherapy, JCI Insight 4 (7) (2019) e126853.
[247] X. Lu, et al., Effective combinatorial immunotherapy for castration-resistant
prostate cancer, Nature 543 (7647) (2017) 728–732.
[248] I. Marigo, et al., Tumor-induced tolerance and immune suppression depend on the
C/EBPbeta transcription factor, Immunity 32 (6) (2010) 790–802.
[249] J. Sceneay, et al., Tracking the Fate of Adoptively Transferred Myeloid-derived
Suppressor Cells in the Primary Breast Tumor Microenvironment, 13 (4) (2018)
e0196040.
[250] F. Lassailly, E. Griessinger, D. Bonnet, “Microenvironmental contaminations” in-
duced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell
tracking, Blood 115 (26) (2010) 5347–5354.
[251] S. Eisenstein, et al., Myeloid-derived suppressor cells as a vehicle for tumor-spe-
cific oncolytic viral therapy, Cancer Res. 73 (16) (2013) 5003–5015.
[252] D. Chandra, A. Jahangir, W. Quispe-Tintaya, M.H. Einstein, C. Gravekamp,
Myeloid-derived suppressor cells have a central role in attenuated Listeria
monocytogenes-based immunotherapy against metastatic breast cancer in young
and old mice, Br. J. Cancer 108 (11) (2013) 2281–2290.
[253] S.H. Kim, F. Castro, Y. Paterson, C. Gravekamp, High efficacy of a Listeria-based
vaccine against metastatic breast cancer reveals a dual mode of action, Cancer Res.
69 (14) (2009) 5860–5866.
[254] K. Newick, S. O’Brien, E. Moon, S.M. Albelda, CAR T cell therapy for solid tumors,
Annu. Rev. Med. 68 (2017) 139–152.
[255] Z. Wang, W. Chen, X. Zhang, Z. Cai, W. Huang, A long way to the battlefront: CAR
T cell therapy against solid cancers, J. Cancer 10 (14) (2019) 3112–3123.
[256] J.D. Peske, A.B. Woods, V.H. Engelhard, Control of CD8 T-cell infiltration into
tumors by vasculature and microenvironment, Adv. Cancer Res. 128 (2015)
263–307.
[257] M. Idorn, P. Thor Straten, Chemokine receptors and exercise to tackle the in-
adequacy of T cell homing to the tumor site, Cells 7 (8) (2018).
[258] K. Suzuki, A. Nakai, Control of lymphocyte trafficking and adaptive immunity by
adrenergic nerves, Clin. Exp. Neuroimmunol. 8 (1) (2017) 15–22.
[259] M.W. Rohaan, S. Wilgenhof, J.B.A.G. Haanen, Adoptive cellular therapies: the
current landscape, Virchows Arch. 474 (4) (2019) 449–461.
[260] B.L. Levine, J. Miskin, K. Wonnacott, C. Keir, Global manufacturing of CAR T cell
therapy, Mol. Ther. Methods Clin. Dev. 4 (2017) 92–101.
[261] J.P. Girard, C. Moussion, R. Forster, HEVs, lymphatics and homeostatic immune
cell trafficking in lymph nodes, Nat. Rev. Immunol. 12 (11) (2012) 762–773.
[262] N. Garbi, B. Arnold, S. Gordon, G.J. Hammerling, R. Ganss, CpG motifs as proin-
flammatory factors render autochthonous tumors permissive for infiltration and
destruction, J. Immunol. (Baltimore, Md. : 1950) 172 (10) (2004) 5861–5869.
[263] R.A. Clark, et al., Human squamous cell carcinomas evade the immune response
by down-regulation of vascular E-selectin and recruitment of regulatory T cells, J.
Exp. Med. 205 (10) (2008) 2221–2234.
[264] M.H. Kershaw, et al., Redirecting migration of T cells to chemokine secreted from
tumors by genetic modification with CXCR2, Hum. Gene Ther. 13 (16) (2002)
1971–1980.
[265] I. Siddiqui, M. Erreni, M. van Brakel, R. Debets, P. Allavena, Enhanced recruitment
of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1
expressing tumors: importance of the chemokine gradient, J. Immunother. Cancer
4 (2016) 21.
[266] A. Di Stasi, et al., T lymphocytes coexpressing CCR4 and a chimeric antigen re-
ceptor targeting CD30 have improved homing and antitumor activity in a Hodgkin
tumor model, Blood 113 (25) (2009) 6392–6402.
F. Combes, et al. Journal of Controlled Release 327 (2020) 70–87
85
[267] J.A. Craddock, et al., Enhanced tumor trafficking of GD2 chimeric antigen receptor
T cells by expression of the chemokine receptor CCR2b, J. Immunother.
(Hagerstown, Md. : 1997) 33 (8) (2010) 780–788.
[268] E.K. Moon, et al., Expression of a functional CCR2 receptor enhances tumor lo-
calization and tumor eradication by retargeted human T cells expressing a me-
sothelin-specific chimeric antibody receptor, Clin. Cancer Res. 17 (14) (2011)
4719–4730.
[269] M. Chmielewski, A.A. Hombach, H. Abken, Of CARs and TRUCKs: chimeric an-
tigen receptor (CAR) T cells engineered with an inducible cytokine to modulate
the tumor stroma, Immunol. Rev. 257 (1) (2014) 83–90.
[270] M. Chmielewski, C. Kopecky, A.A. Hombach, H. Abken, IL-12 release by en-
gineered T cells expressing chimeric antigen receptors can effectively Muster an
antigen-independent macrophage response on tumor cells that have shut down
tumor antigen expression, Cancer Res. 71 (17) (2011) 5697–5706.
[271] E.D. Tait Wojno, C.A. Hunter, J.S. Stumhofer, The immunobiology of the
Interleukin-12 family: room for discovery, Immunity 50 (4) (2019) 851–870.
[272] S.P. Kerkar, et al., Tumor-specific CD8< sup>+</sup>T cells expressing
interleukin-12 eradicate established cancers in lymphodepleted hosts, Cancer Res.
70 (17) (2010) 6725.
[273] L. Zhang, et al., Improving adoptive T cell therapy by targeting and controlling IL-
12 expression to the tumor environment, Mol. Ther. 19 (4) (2011) 751–759.
[274] R.B. Jones, et al., Antigen recognition-triggered drug delivery mediated by na-
nocapsule-functionalized cytotoxic T-cells, Biomaterials 117 (2017) 44–53.
[275] D. Chinnasamy, et al., Local delivery of interleukin-12 using T cells targeting VEGF
receptor-2 eradicates multiple vascularized tumors in mice, Clin. Cancer Res. 18
(6) (2012) 1672–1683.
[276] S. Patel, et al., Beyond CAR T cells: other cell-based immunotherapeutic strategies
against cancer, Front. Oncol. 9 (2019) 196.
[277] M. Martinez, E.K. Moon, CAR T cells for solid tumors: new strategies for finding,
infiltrating, and surviving in the tumor microenvironment, Front. Immunol. 10
(2019) 128.
[278] M. Ruella, S.S. Kenderian, Next-generation chimeric antigen receptor T-cell
therapy: going off the shelf, BioDrugs 31 (6) (2017) 473–481.
[279] P. Bonaventura, et al., Cold tumors: a therapeutic challenge for immunotherapy,
Front. Immunol. 10 (2019) 168.
[280] F. Fang, W. Xiao, Z. Tian, NK cell-based immunotherapy for cancer, Semin.
Immunol. 31 (2017) 37–54.
[281] K. Rezvani, Adoptive cell therapy using engineered natural killer cells, Bone
Marrow Transplant. 54 (2) (2019) 785–788.
[282] N.S. Sta Maria, S.R. Barnes, R.E. Jacobs, In vivo monitoring of natural killer cell
trafficking during tumor immunotherapy, Magn. Reson Insights 7 (2014) 15–21.
[283] R.S. Mehta, K. Rezvani, Chimeric antigen receptor expressing natural killer cells
for the immunotherapy of cancer, Front. Immunol. 9 (2018) 283.
[284] R. Meier, et al., Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-
positive tumors, Nucl. Med. Biol. 35 (5) (2008) 579–588.
[285] B. Santomasso, C. Bachier, J. Westin, K. Rezvani, E.J. Shpall, The other side of CAR
T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial
burden, American Society of Clinical Oncology Educational Book, 39 2019, pp.
433–444.
[286] A.M. Abel, C. Yang, M.S. Thakar, S. Malarkannan, Natural killer cells: develop-
ment, maturation, and clinical utilization, Front. Immunol. 9 (2018) 1869.
[287] J.J. Campbell, et al., Unique subpopulations of CD56+ NK and NK-T peripheral
blood lymphocytes identified by chemokine receptor expression repertoire, J.
Immunol. (Baltimore, Md. : 1950) 166 (11) (2001) 6477–6482.
[288] M. Lima, et al., Chemokine receptor expression on normal blood CD56(+) NK-
cells elucidates cell partners that comigrate during the innate and adaptive im-
mune responses and identifies a transitional NK-Cell population, J Immunol Res
2015 (2015) 839684.
[289] S. Kim, et al., In vivo developmental stages in murine natural killer cell matura-
tion, Nat. Immunol. 3 (6) (2002) 523–528.
[290] T. Tonn, et al., Treatment of patients with advanced cancer with the natural killer
cell line NK-92, Cytotherapy 15 (12) (2013) 1563–1570.
[291] K. Schonfeld, et al., Selective inhibition of tumor growth by clonal NK cells ex-
pressing an ErbB2/HER2-specific chimeric antigen receptor, Mol. Ther. 23 (2)
(2015) 330–338.
[292] D.A. Knorr, et al., Clinical-scale derivation of natural killer cells from human
pluripotent stem cells for cancer therapy, Stem Cells Transl. Med. 2 (4) (2013)
274–283.
[293] Y. Li, D.L. Hermanson, B.S. Moriarity, D.S. Kaufman, Human iPSC-derived natural
killer cells engineered with chimeric antigen receptors enhance anti-tumor ac-
tivity, Cell Stem Cell 23 (2) (2018) 181–192 (e185).
[294] E.L. Siegler, Y. Zhu, P. Wang, L. Yang, Off-the-shelf CAR-NK cells for cancer im-
munotherapy, Cell Stem Cell 23 (2) (2018) 160–161.
[295] R.H. Goldfarb, et al., A novel drug delivery system using IL-2 activated NK cells
and Zyn-linked doxorubicin, In Vivo (Athens, Greece) 14 (1) (2000) 101–104.
[296] S. Li, et al., Nanomedicine engulfed by macrophages for targeted tumor therapy,
Int. J. Nanomedicine 11 (2016) 4107–4124.
[297] T. Lang, et al., Ly6Chi monocytes delivering pH-sensitive micelle loading pacli-
taxel improve targeting therapy of metastatic breast cancer, Adv. Funct. Mater. 27
(26) (2017) 1701093.
[298] H. Dou, et al., Macrophage delivery of nanoformulated antiretroviral drug to the
brain in a murine model of neuroAIDS, J. Immunol. (Baltimore, Md. : 1950) 183
(1) (2009) 661–669.
[299] H.I. Tong, et al., Monocyte trafficking, engraftment, and delivery of nanoparticles
and an exogenous gene into the acutely inflamed brain tissue - evaluations on
monocyte-based delivery system for the central nervous system, PLoS One 11 (4)
(2016) e0154022.
[300] D. Chu, X. Dong, Q. Zhao, J. Gu, Z. Wang, Photosensitization Priming of Tumor
Microenvironments Improves Delivery of Nanotherapeutics via Neutrophil
Infiltration, 29(27) (2017).
[301] T. Takeshima, et al., Key role for neutrophils in radiation-induced antitumor im-
mune responses: potentiation with G-CSF, Proc. Natl. Acad. Sci. U. S. A. 113 (40)
(2016) 11300–11305.
[302] D. Chu, et al., Nanoparticle targeting of neutrophils for improved cancer im-
munotherapy, Adv. Healthc. Mater. 5 (9) (2016) 1088–1093.
[303] F. Combes, S. Mc Cafferty, E. Meyer, N.N. Sanders, Off-target and tumor-specific
accumulation of monocytes, macrophages and myeloid-derived suppressor cells
after systemic injection, Neoplasia (New York, N.Y.) 20 (8) (2018) 848–856.
[304] A. Fraternale, et al., Macrophage protection by addition of glutathione (GSH)-
loaded erythrocytes to AZT and DDI in a murine AIDS model, Antivir. Res. 56 (3)
(2002) 263–272.
[305] V.R. Muzykantov, M.D. Smirnov, A.L. Klibanov, Avidin attachment to red blood
cells via a phoshpolipid derivative of biotin provides complement-resistant im-
munoerythrocytes, J. Immunol. Methods 158 (2) (1993) 183–190.
[306] E. Bohmova, et al., Cell-penetrating peptides: a useful tool for the delivery of
various cargoes into cells, Physiol. Res. 67 (Suppl. 2) (2018) S267–s279.
[307] C.M. Hu, et al., Erythrocyte membrane-camouflaged polymeric nanoparticles as a
biomimetic delivery platform, Proc. Natl. Acad. Sci. U. S. A. 108 (27) (2011)
10980–10985.
[308] A. Parodi, et al., Synthetic nanoparticles functionalized with biomimetic leukocyte
membranes possess cell-like functions, Nat. Nanotechnol. 8 (1) (2013) 61–68.
[309] H. Zhang, et al., Biointerface engineering nanoplatforms for cancer-targeted drug
delivery, Asian J. Pharm. Sci. (2019) (in press).
[310] A.C. Anselmo, S. Mitragotri, Cell-mediated delivery of nanoparticles: taking ad-
vantage of circulatory cells to target nanoparticles, J. Control. Release 190 (2014)
531–541.
[311] A.C. Anselmo, et al., Delivering nanoparticles to lungs while avoiding liver and
spleen through adsorption on red blood cells, ACS Nano 7 (12) (2013)
11129–11137.
[312] X. Chen, et al., Interfacing carbon nanotubes with living cells, J. Am. Chem. Soc.
128 (19) (2006) 6292–6293.
[313] M.T. Stephan, J.J. Moon, S.H. Um, A. Bershteyn, D.J. Irvine, Therapeutic cell
engineering with surface-conjugated synthetic nanoparticles, Nat. Med. 16 (9)
(2010) 1035–1041.
[314] D. Sarkar, et al., Chemical engineering of mesenchymal stem cells to induce a cell
rolling response, Bioconjug. Chem. 19 (11) (2008) 2105–2109.
[315] M.T. Stephan, D.J. Irvine, Enhancing cell therapies from the outside in: cell surface
engineering using synthetic nanomaterials, Nano Today 6 (3) (2011) 309–325.
[316] M.R. Choi, et al., A cellular Trojan Horse for delivery of therapeutic nanoparticles
into tumors, Nano Lett. 7 (12) (2007) 3759–3765.
[317] R.J. Melder, C.A. Kristensen, L.L. Munn, R.K. Jain, Modulation of A-NK cell ri-
gidity: in vitro characterization and in vivo implications for cell delivery,
Biorheology 38 (2–3) (2001) 151–159.
[318] C. Perez-Campana, et al., Biodistribution of different sized nanoparticles assessed
by positron emission tomography: a general strategy for direct activation of metal
oxide particles, ACS Nano 7 (4) (2013) 3498–3505.
[319] N. Hoshyar, S. Gray, H. Han, G. Bao, The effect of nanoparticle size on in vivo
pharmacokinetics and cellular interaction, Nanomedicine (London, England) 11
(6) (2016) 673–692.
[320] C. Zhang, et al., Labeling stem cells with a near-infrared fluorescent heptamethine
dye for noninvasive optical tracking, Cell Transplant. 20 (5) (2011) 741–751.
[321] J. Gao, J.E. Dennis, R.F. Muzic, M. Lundberg, A.I. Caplan, The dynamic in vivo
distribution of bone marrow-derived mesenchymal stem cells after infusion, Cells
Tissues Organs 169 (1) (2001) 12–20.
[322] Y.J. Choi, et al., Visualization of the biological behavior of tumor-associated
macrophages in living mice with colon cancer using multimodal optical reporter
gene imaging, Neoplasia (New York, N.Y.) 18 (3) (2016) 133–141.
[323] J. Leibacher, R. Henschler, Biodistribution, migration and homing of systemically
applied mesenchymal stem/stromal cells, Stem Cell Res Ther 7 (1) (2016) 7.
[324] D. Ritchie, et al., In vivo tracking of macrophage activated killer cells to sites of
metastatic ovarian carcinoma, Cancer Immunol. Immunother. 56 (2) (2007)
155–163.
[325] C.A. Boswell, et al., Comparative physiology of mice and rats: radiometric mea-
surement of vascular parameters in rodent tissues, Mol. Pharm. 11 (5) (2014)
1591–1598.
[326] M. Eltze, Functional evidence for an alpha 1B-adrenoceptor mediating contraction
of the mouse spleen, Eur. J. Pharmacol. 311 (2–3) (1996) 187–198.
[327] R.J. Shephard, Responses of the human spleen to exercise, J. Sports Sci. 34 (10)
(2016) 929–936.
[328] R.J. Melder, et al., Systemic distribution and tumor localization of adoptively
transferred lymphocytes in mice: comparison with physiologically based phar-
macokinetic model, Neoplasia (New York, N.Y.) 4 (1) (2002) 3–8.
[329] F. Combes, A.M. Sofias, Mononuclear but Not Polymorphonuclear Phagocyte
Depletion Increases Circulation Times and Improves Mammary Tumor-homing
Efficiency of Donor Bone Marrow-derived Monocytes, 11(11) (2019).
[330] S.P. Davies, G.M. Reynolds, Z. Stamataki, Clearance of apoptotic cells by tissue
epithelia: a putative role for hepatocytes in liver efferocytosis, Front. Immunol. 9
(2018) 44.
[331] Bosman GJCGM, Survival of red blood cells after transfusion: processes and con-
sequences, Front. Physiol. 4 (2013) 376.
[332] K.S. Ravichandran, Beginnings of a good apoptotic meal: the find-me and eat-me
signaling pathways, Immunity 35 (4) (2011) 445–455.
F. Combes, et al. Journal of Controlled Release 327 (2020) 70–87
86
[333] S. Krahling, M.K. Callahan, P. Williamson, R.A. Schlegel, Exposure of phosphati-
dylserine is a general feature in the phagocytosis of apoptotic lymphocytes by
macrophages, Cell Death Differ. 6 (2) (1999) 183–189.
[334] D.E. Discher, How does CD47-SIRPα ‘don’t eat me signal’ physically signal self,
Blood 122 (21) (2013) 953.
[335] E.M. Carrington, et al., Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate
collectively to maintain survival of immune cell populations both in vitro and in
vivo, Cell Death Differ. 24 (2017) 878.
[336] A. Kurtz, Mesenchymal stem cell delivery routes and fate, Int. J. Stem Cells 1 (1)
(2008) 1–7.
[337] E. Kolaczkowska, P. Kubes, Neutrophil recruitment and function in health and
inflammation, Nat. Rev. Immunol. 13 (3) (2013) 159–175.
[338] Y. Ueda, D.W. Cain, M. Kuraoka, M. Kondo, G. Kelsoe, IL-1R type I-dependent
hemopoietic stem cell proliferation is necessary for inflammatory granulopoiesis
and reactive neutrophilia, J. Immunol. (Baltimore, Md. : 1950) 182 (10) (2009)
6477–6484.
[339] J.J. Cream, Prednisolone-induced granulocytosis, Br. J. Haematol. 15 (3) (1968)
259–268.
[340] Y. Shoenfeld, Y. Gurewich, L.A. Gallant, J. Pinkhas, Prednisone-induced leuko-
cytosis. Influence of dosage, method and duration of administration on the degree
of leukocytosis, Am. J. Med. 71 (5) (1981) 773–778.
[341] M. Nakagawa, et al., Glucocorticoid-induced granulocytosis: contribution of
marrow release and demargination of intravascular granulocytes, Circulation 98
(21) (1998) 2307–2313.
[342] D.M.H. Cavalcanti, et al., Endogenous glucocorticoids control neutrophil mobili-
zation from bone marrow to blood and tissues in non-inflammatory conditions, Br.
J. Pharmacol. 152 (8) (2007) 1291–1300.
[343] S. Ronchetti, E. Ricci, G. Migliorati, M. Gentili, C. Riccardi, How glucocorticoids
affect the neutrophil life, Int. J. Mol. Sci. 19 (12) (2018) 4090.
[344] G. von Maltzahn, et al., Nanoparticles that communicate in vivo to amplify tumour
targeting, Nat. Mater. 10 (7) (2011) 545–552.
[345] A.M. Sofias, T. Andreassen, S. Hak, Nanoparticle ligand-decoration procedures
affect in vivo interactions with immune cells, Mol. Pharm. 15 (12) (2018)
5754–5761.
[346] A.N. Miliotou, L.C. Papadopoulou, CAR T-cell therapy: a new era in cancer im-
munotherapy, Curr. Pharm. Biotechnol. 19 (1) (2018) 5–18.
[347] C. Fountzilas, S. Patel, D. Mahalingam, Review: oncolytic virotherapy, updates and
future directions, Oncotarget 8 (60) (2017) 102617–102639.
[348] I.C. Miller, M. Gamboa Castro, J. Maenza, J.P. Weis, G.A. Kwong, Remote control
of mammalian cells with heat-triggered gene switches and photothermal pulse
trains, ACS Synth. Biol. 7 (4) (2018) 1167–1173.
[349] S. Goverdhana, et al., Regulatable gene expression systems for gene therapy ap-
plications: progress and future challenges, Mol. Ther. 12 (2) (2005) 189–211.
[350] G. Zhong, H. Wang, C.C. Bailey, G. Gao, M. Farzan, Rational design of aptazyme
riboswitches for efficient control of gene expression in mammalian cells, eLife 5
(2016) e18858.
[351] B.D. Brown, M.A. Venneri, A. Zingale, L. Sergi Sergi, L. Naldini, Endogenous
microRNA regulation suppresses transgene expression in hematopoietic lineages
and enables stable gene transfer, Nat. Med. 12 (5) (2006) 585–591.
[352] A. Aalipour, et al., Engineered immune cells as highly sensitive cancer diagnostics,
Nat. Biotechnol. 37 (2019) 531–539.
[353] M. Rath, I. Muller, P. Kropf, E.I. Closs, M. Munder, Metabolism via arginase or
nitric oxide synthase: two competing arginine pathways in macrophages, Front.
Immunol. 5 (2014) 532.
F. Combes, et al. Journal of Controlled Release 327 (2020) 70–87
87
